DIRECTORY
BIOTECH
Pharmaclient

   

Quick Click ! Monthly news Home-Site Menu-Site Contactexpress Faqs Legends Companies Events Environment Memories Home-Biotech

A B C D E F G H I J K L M
N O P Q R S T U V W X Y Z

EVENTS & NEWS - ACTUALITÉS        

 

légende

légende

  • How to use this synthetic global (and long) page : surf the table, re-organise the table (sort it with one click or two clicks on a column title), direct access to a given active company by pointing their initials above after sorting column 1 by increasing order (all explanations in 'Legends', full details of a given company in 'Companies', in the above toolbar)
  • To read latest news, click twice on 'Date' column
  • Note : in this page, events are kept concerning 'Memories' companies in the end (with the sign : ǂ after the name)
  • Comment utiliser cette page globale (longue!) de synthèse : parcourir le tableau, ré-organiser le tableau (tri par un clic ou deux clics sur une colonne), accès direct à une société en pointant son initiale ci-dessus, après tri alphabétique de la colonne 1 (toutes explications dans 'Legends', détail complet d'une société dans 'Companies', dans la barre ci-dessus)
  • Pour lire les dernières Infos, cliquer 2 fois sur la colonne 'Date'
  • Note : dans cette page, les évènements concernant les sociétés listées à 'Memories' sont conservés à la fin (avec le signe : ǂ après le nom)

 

COMPANY DATE MAJOR EVENT TYPE CLOCK
AbAglégende 2003 .10 Round-financing : undisclosed M€, by OTC Innovation RFIN [3 years]
Abcys 1999 .12 Company founded by Jean-Pierre Mouscadet and Thierry Martin ORGF [0 year]
AB Science 2012 .03 Financing (interest loan) : 10.0 M€, in convertible bonds DEBT [10 years]
AB Science 2011 .04 Financing (interest loan) : 7.5 M€, by existing shareholders (eurobonds) DEBT [9 years]
AB Science 2010 .10 Clinical trial (phase III) for masitinib in 3 types of cancers (pancreatic, mastocytosis and gastro-intestinal), in EU and USA (beginning, in total 9 trials) CLIN [9 years]
AB Science 2010 .05 Listing on Euronext Paris : 31.6 M€ (55.0 M€ expected) PBO [8 years]
AB Science 2008 .09 Registration : positive opinion from EMEA for lead compound masitinib in the treatment of canine mast cell tumor MKTG [7 years]
AB Science 2007 .05 Court : legal prosecution against Medicen, Paris Pôle de Compétitivité, with a claim of 125 M€ LEGAL [5 years]
AB Science 2001 .07 Company founded by Alain Moussy ORGF [0 year]
Adocia 2012 .06 Patent : granted on BioChaperone PDGF (Platelet Derived Growth Factor) formulations for chronic wound treatment, including Diabetic Foot Ulcer, in USA (USPTO) and Europe (EPO) LEGAL [6 years]
Adocia 2012 .04 Clinical trials (phase II) with PDGF-BB for the treatment of diabetic foot ulcer, compared with current standard Regranex (results, phase III planned to start end of 2012) CLIN [6 years]
Adocia 2012 .02 Listing on Euronext : 25.3 M€ (IPO), extended to 27.4 M€ in April PBO [6 years]
Adocia 2011 .06 Clinical trials (phase II) with BioChaperone technology combined with 2 therapeutic proteins, Platelet Derived Growth Factor, fast-acting human insulin (completed) CLIN [5 years]
Adocia 2011 .03 Clinical trial (phase I) for HinsBet, a fast-acting human insulin (completed, positive, with phase IIa, started in May) CLIN [5 years]
Adocia 2010 .01 2nd round-financing : 14.0 M€, by InnoBio (for 6 M€), SHAM (for 2 M€), and previous shareholders, including the founders RFINB [4 years]
Adocia 2008 .04 1st round-financing : 12.0 M€, by AGF P.E., Société Générale A.M., Bioam Gestion, Vivéris Management RFINA [2 years]
Adocia 2007 .00 Financing (no interest loan) : 2.25 M€, by Oseo, for its osteoporosis project DEBT [1 year]
Adocia 2005 .12 Company founded by Gérard Soula (ex-Flamel Technologies, CEO, during 15 years), and his 2 sons, Olivier (born 1970) and Rémy, initially named PPM (Proteins & Peptides Management), investing 1.6 M€ ORGF [0 year]
Advicenne Pharma 2011 .05 2nd round-financing : 5.1 M€, by InnoBio (for 3 M€), Ixo Private Equity (1.25 M€), and previous shareholders RFINB [4 years]
Advicenne Pharma 2008 .00 1st round-financing : 1.0 M€, by undisclosed investors RFINA [0 year]
Advicenne Pharma 2007 .04 Company founded by Luc-André Granier ORGF [0 year]
Affichem 2007 .01 Partnering research agreement with SAFC to provide chemical development services for Dendrogenine A, a potential cancer treatment R&D [4 years]
Affichem 2002 .10 Company founded by 2 Inserm researchers, Marc and Sandrine Poirot, and by Philippe Rivière and Stéphane Silvente ORGF [0 year]
Agate Bioservices 2005 .04 Company founded by Hassan Chaabihi, within École des Mines d'Alès (EMA engineers' school) ORGF [0 year]
Aisa Therapeutics 2007 .10 Seed financing : undisclosed M€, by 2 business angels SFIN [2 years]
Aisa Therapeutics 2005 .10 Company founded by Patrizia d'Alesso (Inserm), with Aisa meaning Anti Inflammatory Senescence Actives ORGF [0 year]
Alfact Innovation 2010 .02 Clinical trial (phase II) for ALF-5755 in patients with nonacetaminophen severe acute hepatitis and early stage acute liver failure (beginning) CLIN [4 years]
Alfact Innovation 2009 .12 Clinical trial (phase I) for ALF-5755 (completed) CLIN [3 years]
Alfact Innovation 2009 .04 Registration : orphan Drug designation by EMA for ALF-5755 (treatment of Acute Liver Failure) [same decision by FDA in May 2011] MKTG [3 years]
Alfact Innovation 2006 .01 Company founded by Gilles Amouyal and Paul Amouyal (chairman, born 1955, M.D.), with Marc Le Bozec as COO (up to October 2006), from technological tools exclusively licensed from Inserm ORGF [0 year]
Alizé Pharma 2013 .01 Partnering R&D agreement for Premag, a consortium with scinetific institutions, Ricerca Biosciences, and Bertin Pharma on unacylated ghrelin (AZP-531) in muscular protection and regeneration R&D [5 years]
Alizé Pharma 2012 .02 Licensing-out of Asparec for treatment of Acute Lymphoblastic Leukemia (ALL) to Eusa Pharma (worldwide) LICOUT [4 years]
Alizé Pharma 2010 .01 Partnering R&D agreement with Eli Lilly (USA) on unacylated ghrelin (AZP-01) program for the treatment of type II diabetes (with licence option) R&D [2 years]
Alizé Pharma 2009 .09 1st round-financing : 3.0 M€, by SHAM and previous investors RFINA [2 years]
Alizé Pharma 2008 .05 Licensing-in of preclinical recombinant L-asparaginase program for the treatment of acute lymphoblastic leukaemia, a lead compound from EUSA Pharma (USA) LICIN [1 year]
Alizé Pharma 2007 .09 Seed financing : 0.7 M€, by 2 private companies, Octalfa (Gilles Alberici), CEMA (Canada, André de Villers) SFIN [0 year]
Alizé Pharma 2007 .04 Company founded by Thierry Abribat and André de Villers [co-financer, M.D., ex-Theratechnologies] ORGF [0 year]
Ambiotis 2010 .00 Seed financing : 0.13 M€, by private investors and WiSEED SFIN [2 years]
Ambiotis 2009 .03 Company website completed and revamped in 2 languages INFO [1 year]
Ambiotis 2008 .00 Financing (no interest loan) : 0.75 M€, by OSEO, for its R&D programme DEBT [0 year]
Ambiotis 2007 .03 Company founded by Marc Dubourdeau (initially named as 2iPharma) ORGF [0 year]
Anaconda Pharma 2009 .04 Financing (no interest loan) : 0.5 M€, by OSEO (already a similar funding in 2004) DEBT [5 years]
Anaconda Pharma 2008 .05 Company move from Paris Pasteur Biotop incubator to Paris Biopark with new R&D facilities ORGL [4 years]
Anaconda Pharma 2007 .01 Round-financing : 2.6 M€, by private investors RFIN [3 years]
Anaconda Pharma 2006 .10 Financing : leader company in the CristaLead Program, with a minimum of € 1 Million grant RFIN [3 years]
Anaconda Pharma 2003 .10 Company founded by Dr Moshe Yaniv and Dr Françoise Thierry (both from Institut Pasteur), Dr Michael Botchan (Berkeley), and Marta Blumenfeld and Jean-Michel Gauthier, as a spin-off from Institut Pasteur ORGF [0 year]
Aptys Pharmaceuticals 2012 .05 Clinical trial (phase III) for a new formulation product based on the Bi-Gel technology in the USA, additonal study to be performed in 2013 due to FDA request CLIN [9 years]
Aptys Pharmaceuticals 2008 .12 Seed financing : 0.5 M€, led by Sofimac Partners, with contribution of CACF Développement (Crédit Agricole Centre France) SFIN [6 years]
Aptys Pharmaceuticals 2007 .05 Clinical trial (phase III) for a new formulation product based on the Bi-Gel technology in the USA (beginning) CLIN [4 years]
Aptys Pharmaceuticals 2004 .02 Launch of new trade mark as «The Formulation Company» MKTG [1 year]
Aptys Pharmaceuticals 2002 .11 Company founded by François Boutignon, Jean-Marc Aiache [Pharm.D., Ph.D., Professor Emeritus], and Michel G. Lepers [Professor of Technology transfer at University of Auvergne, founder-CEO Eurobiobiz], as a spin-off of the University of Auvergne ORGF [0 year]
Ariana Pharmaceuticals 2012 .05 Set-up of US subsidiary in Cambridge, Massachussetts (to distribute its data analytics technology KEM) ORGC [8 years]
Ariana Pharmaceuticals 2010 .11 R&D partnering with Bio-Rad, INSERM and Beaujon Hospital on Hepachronix project, for new biomarkers R&D [7 years]
Ariana Pharmaceuticals 2010 .02 R&D partnering with Fovea on Phase II clinical data analysis, with KEM clinicals, a new version of its decision support platform KEM (undisclosed fees) R&D [6 years]
Ariana Pharmaceuticals 2009 .08 Financing (no interest loan) : 10.0 M€, by OSEO Innovation, for oncology biomarker program IMAkinib (with Oncodesign and Guerbet) [Ariana part : 1.0 M€] DEBT [6 years]
Ariana Pharmaceuticals 2008 .07 1st round-financing : 1.5 M€, by Vizille Capital Innovation (Crédit Mutuel - CIC) RFINA [4 years]
Ariana Pharmaceuticals 2008 .03 Launch of new KEM multi-objective data analysis and decision support MKTG [4 years]
Ariana Pharmaceuticals 2005 .12 Licensing-out of KM platform to Institut Pasteur, against a minority share LICOUT [2 years]
Ariana Pharmaceuticals 2003 .08 Company founded by Mohamma Afshar and others, as a spin-off from Institut Pasteur ORGF [0 year]
Aterovax 2010 .08 Partnering distribution agreement for sPLA2 Activity Test with Biomnis (ex-Mérieux) MKTG [4 years]
Aterovax 2010 .04 Partnering distribution agreement for sPLA2 Activity Test in Europe with SPI-BIO (research use, only, for 3 years) MKTG [3 years]
Aterovax 2009 .11 Research : publication in European Heart Journal of Clinical of trial evaluating systemic sPLA2 association with prognosis in patients with coronary heart disease (1024 patients with CHD) R&D [3 years]
Aterovax 2009 .11 Clinical trial (phase III) for sPLA2 activity, as a stronger marker for risk prediction (ending) CLIN [3 years]
Aterovax 2008 .07 Financing : grant of 1.45 M€, by ANR, for the cardiovascular therapy program RFIN [2 years]
Aterovax 2008 .06 Prize : Siemens Innovation Price 2008 (Health) MKTG [2 years]
Aterovax 2006 .07 Seed financing : 3.0 M€ by SGAM (Specialized European Fund for Therapeutic Innovation) SFIN [0 year]
Aterovax 2006 .06 Company founded by Alain Tedgui, Ziad Mallat, and others, from Inserm exclusive worldwide rights to 3 filed patents covering current biomarker products and the immunotherapy program ORGF [0 year]
Atlantic Bone Screen 2008 .05 Acquisition of Atlanchim, molecular chemical synthesis subcontractor (at book value, plus 5 maintained jobs) ACQ+ [2 years]
Atlantic Bone Screen 2005 .11 Company founded by Ronan Le Bot, Dr Dominique Heymann, Dr Françoise Redini, Dr Marc Padrines, Dr Yannick Fortun, and Prof. François Gouin ORGF [0 year]
Aureus Sciences 2011 .01 Company rename as Aureus Sciences (from Aureus Pharma) with no change in capital structure, and with a new, comprehensive life science applications webportal ORGL [11 years]
Aureus Sciences 2010 .03 R&D partnering in Biointelligence R&D programme of € 118 Millions, designed to promote the use of systemic modeling and simulation tools to exploit biomedical databases and coordinated by Dassault Systèmes (with notably Sanofi-Aventis, Ipsen, Servier, Pierre Fabre, Bayer) R&D [10 years]
Aureus Sciences 2010 .02 Licensing-out of DDI Project 2009 to Sanofi-Aventis LICOUT [10 years]
Aureus Sciences 2008 .08 Launch of new software solution AurPROFILER (to rapidly evaluate target, cell and drug profiles using bio-assays) MKTG [8 years]
Aureus Sciences 2007 .11 Licensing-out of Aurscope GPCR to BMS (renewal) LICOUT [7 years]
Aureus Sciences 2002 .11 Licensing-out to Servier and Aventis LICOUT [2 years]
Aureus Sciences 2006 .12 Nomination : Jason Theodosiou, new CEO, André Michel, founder, moved to supervisory board ORGN [6 years]
Aureus Sciences 2004 .10 1st round-financing : 3.0 M€, by OTC A.M., AXA P.E., and previous shareholders RFINA [4 years]
Aureus Sciences 2002 .01 Company (holding of Aureus as an SCP) founded by Dr André Michel ORGF [2 years]
Aureus Sciences 2000 .09 Seed financing : 0.8 M€, by Bioam SFIN [0 year]
Aureus Sciences 2000 .01 Company founded by Dr André Michel [born 1944, CEO, Ph.D. chemistry, Namur, ex-Servier, Neokimia] ORGF [0 year]
BCell Designlégende 2008 .03 Seed financing : 0.1 M€, by Limousin Participation, Limousin Expansion, Limousin Business Angels SFIN [0 year]
B Cell Design 2008 .01 Company founded by Michel Cogné (SAB), Armelle Cuvillier, based on a patent from Limoges University ORGF [0 year]
BioAlliance Pharma 2013 .04 Registration : positive FDA approval for acyclovir Lauriad (Sitavig) in USA MKTG [16 years]
BioAlliance Pharma 2012 .12 Registration : positive EMA approval for acyclovir Lauriad (Sitavig) in Europe MKTG [15 years]
BioAlliance Pharma 2012 .07 Licensing-out of US commercialization rights for Oravig (known as Loramyc in Europe) for the treatment of oropharyngeal candidiasis in adults, to US company Vestiq LICOUT [15 years]
BioAlliance Pharma 2012 .01 Clinical trial (phase I) for AMEP biotherapy in the metastatic melanoma (beginning, ended October 2012) and grant of a European patent covering the product until 2022 CLIN [14 years]
BioAlliance Pharma 2011 .11 Registration : orphan Drug designation by EMA for clonidine Lauriad in Europe CLIN [14 years]
BioAlliance Pharma 2011 .07 Public offering : 16.6 M€, as a capital increase RFIN [14 years]
BioAlliance Pharma 2011 .06 Nomination : Judith Greciet as CEO (previously COO), while Dominique Costantini, co-founder, born 1955, retires ORGN [14 years]
BioAlliance Pharma 2011 .03 Clinical trial (phase II) for Livatag (doxorubicin Transdrug), positive on survival in advanced hepatocellular carcinoma patients CLIN [14 years]
BioAlliance Pharma 2010 .09 Patent : granted on Lauriad (drug delivery for acyclovir), in Europe LEGAL [13 years]
BioAlliance Pharma 2010 .04 Registration : positive US FDA approval for Oravig (Loramyc in EU) with US$ 20 Million milestone payment from Strativa Pharmaceuticals, the commercial partner in the US MKTG [13 years]
BioAlliance Pharma 2010 .04 Licensing-out of European commercialization rights for Loramyc and Setofilm to Therabel (Belgium) in a € 48.5 Million deal LICOUT [13 years]
BioAlliance Pharma 2009 .12 Clinical trial (phase II) for Clonidine Lauriad (beginning) in radiotherapy and chemotherapy-induced oral mucositis and clinical trial (phase I) for AMEP (beginning) in invasive melanoma CLIN [12 years]
BioAlliance Pharma 2009 .10 Clinical trial (phase I) for Fentanyl Lauriad, slow-release central analgesic in cancer patients (beginning) CLIN [12 years]
BioAlliance Pharma 2009 .04 Clinical trial planned, after first preclinical trial results on new oral Irinotecan nanoparticle formulation for the treatment of advanced colorectal cancer CLIN [12 years]
BioAlliance Pharma 2009 .04 Financing (no interest loan) : 6.3 M€, by OSEO Innovation, to support Cancer Anti-invasive Program (CAP) private-public consortium (with Oroxcell and Xentech) DEBT [12 years]
BioAlliance Pharma 2009 .03 Licensing-out of Loramyc rights to SpeBio (2007) in Europe regained (withdrawn contract and legal suite) LICOUT [12 years]
BioAlliance Pharma 2009 .02 Registration : submission to EMEA of ondansetron RapidFilm MKTG [11 years]
BioAlliance Pharma 2008 .12 Management restructuring : 9 heads employee reduction, i.e. 12% of total headcounts ORGR [11 years]
BioAlliance Pharma 2008 .09 Financing : capital investment by AGF Private Equity (over 5% of equity) RFIN [11 years]
BioAlliance Pharma 2008 .08 Nomination : Pierre Morgon as COO, along Gilles Avenard (Pierre Morgon resigns in May 2009) ORGN [11 years]
BioAlliance Pharma 2008 .05 Licensing-in of European rights of Ondansetron spray from NovaDel LICIN [11 years]
BioAlliance Pharma 2008 .03 Company (as Laboratory BioAlliance Pharma) founded by Dominique Costantini for Marketing and Trade ORGF [11 years]
BioAlliance Pharma 2007 .09 Launch of Loramyc on French market MKTG [10 years]
BioAlliance Pharma 2007 .07 4th round-financing : 40.0 M€, led by Bryan, Garnier & Co, with international investors (private capital increase) RFIND [10 years]
BioAlliance Pharma 2007 .03 Licensing-out of Loramyc to PAR pharmaceuticals in USA, in a deal valued 95 MUS$ (15 MUS$ initially, plus milestones) LICOUT [10 years]
BioAlliance Pharma 2006 .10 Registration : obtained for Loramyc, in France MKTG [9 years]
BioAlliance Pharma 2005 .12 Public offering : 30.0 M€, Alternext, Eurolist PBO [8 years]
BioAlliance Pharma 2004 .08 3rd round-financing : 2.0 M€ (follow-up), by Siparex Ventures RFINC [7 years]
BioAlliance Pharma 2003 .05 3rd round-financing : 10.0 M€, led by Auriga Partners RFINC [6 years]
BioAlliance Pharma 2000 .05 2nd round-financing : 7.0 M€, by Technolife, ABN-Amro, Spef, and previous shareholders RFINB [3 years]
BioAlliance Pharma 1999 .09 1st round-financing : 1.5 M€, by 3i, Capricorn Venture, and a business angel RFINA [2 years]
BioAlliance Pharma 1997 .03 Company founded by Dominique Costantini and Gilles Avenard ORGF [0 year]
Biocortech 2011 .04 Partnering research agreement with the FondaMental foundation to validate biomarkers for personalized psychiatry (blood tests) R&D [9 years]
Biocortech 2010 .04 Licensing-out of BC-19, an eburnamin derivative to Marco Polo, against an undisclosed package LICOUT [8 years]
Biocortech 2009 .09 Patent : granted on new blood diagnostic test of depression (USA), relating to RNA edition of serotonine 5HT2c receptor LEGAL [7 years]
Biocortech 2009 .04 Clinical trial to validate the concept of a blood test to diagnose and monitor treatment of mood disorders and depression, in France (beginning) CLIN [7 years]
Biocortech 2008 .03 Patent : granted on small molecule antidepressant LEGAL [6 years]
Biocortech 2006 .11 Partnering research agreement with Servier on novel drugs to treat CNS disorders R&D [5 years]
Biocortech 2001 .11 Company founded by Dinah Weissmann and Jean-François Pujol ORGF [0 year]
BioCydex 2008 .01 Launch of Solvamax in London (UK) MKTG [5 years]
BioCydex 2002 .12 Company founded by Yves Cenatiempo and Mustapha Bengsir ORGF [0 year]
Biométhodes 2011 .10 Financing (no interest loan) : 0.7 M€, by OSEO, for the development and industrialization of enzymes DEBT [13 years]
Biométhodes 2011 .03 Set-up of OptaFuel US, based in Abingdon, Virginia, with plans to build a pilot plant ORGC [13 years]
Biométhodes 2008 .06 Licensing-in of processes of biomass to bioethanol and biohydrogen from Virginia Tech Intellectual Properties (USA) LICIN [10 years]
Biométhodes 2007 .12 Patent : granted on Massive Mutagenesis LEGAL [10 years]
Biométhodes 2007 .11 Nomination : Gilles Amsallem as CEO [ex-Finance Director], taking over from founder Marc Delcourt (as CSO, first, then leaving to found Global Bioenergiesin 2008) ORGN [9 years]
Biométhodes 2006 .02 Partnering research agreement with Sanofi-Aventis to develop Solexis, a new technology R&D [8 years]
Biométhodes 2004 .05 Licensing-out of Massive Mutagenesis to Aventis Pharma for R&D optimization LICOUT [6 years]
Biométhodes 2003 .10 2nd round-financing : 4.5 M€, by CDC Innovation, CIC Capital, FCJE (CDC) RFINB [5 years]
Biométhodes 1997 .11 Company founded by Marc Delcourt ORGF [0 year]
Biom'up 2012 .10 3rd round-financing : 6.8 M€, by existing investors, plus 3 new investors, InnoBio, Viveris Management and OTC Asset Management RFINC [7 years]
Biom'up 2010 .09 Registration : FDA first clearance for Cova MAX MKTG [5 years]
Biom'up 2010 .06 2nd round-financing : 3 M€, by SHAM, Sofimac Partners, and Ameliane RFINB [5 years]
Biom'up 2009 .00 1st round-financing : 1.5 M€, by Aquasourça (Euroainvest) RFINA [3 years]
Biom'up 2006 .07 Certification : ISO9001, ISO13485 for design, development, production INFO [1 year]
Biom'up 2005 .02 Company founded by Sylvain Picot, Patricia Forest, Christian Gagnieu, as a spin-off from Laboratoire des Biomatériaux, University of Pharmacie (Lyon) ORGF [0 year]
BioProtein Technologies 2010 .05 3rd round-financing : 0.52 M€, by existing investors RFINC [11 years]
BioProtein Technologies 2009 .09 Set-up of Transgenic Rabbit Models (TRM), a subsidiary servicing company dedicated to the development and supply of genetically modified rabbit models (www.transgenic-rabbit-models.com) ORGC [11 years]
BioProtein Technologies 2006 .12 Set-up of Bioprotein Transgenics, a subsidiary ORGC [8 years]
BioProtein Technologies 2006 .03 Company move from Paris to Jouy-en-Josas (IDF), within INRA premices, in order to join own existing laboratories ORGL [7 years]
BioProtein Technologies 2006 .10 Nomination : Jean Lignel as CEO (replacing CEO and founder, Marc Le Bozec) ORGN [8 years]
BioProtein Technologies 2003 .04 2nd round-financing : 1.5 M€, by previous investors RFINB [4 years]
BioProtein Technologies 2001 .05 1st round-financing : 8.0 M€, by Société Générale A.M., Gilde, Creagro, Iwic, Anvar RFINA [2 years]
BioProtein Technologies 1998 .06 Company founded by 3 INRA scientists involved in transgenic animal and cloning research, Louis-Marie Houdebine, Jean-Paul Renard and Bernard Jégou, and an experienced manager from the business consultancy world, Marc Le Bozec ORGF [0 year]
BioQuanta 2010 .02 Round-financing : 0.5 M€ (US$ 800 000) from private investors RFIN [7 years]
BioQuanta 2006 .03 Set-up of BioQuanta Diagnostics ORGC [3 years]
BioQuanta 2003 .04 Seed financing : undisclosed M€, by private investors SFIN [0 year]
BioQuanta 2003 .02 Company founded by Jean-Michel Mauclaire and others, in Aurora (USA) as BioQuanta Inc. and set-up of subsidiary in France (SaRL) ORGF [0 year]
BioSystems International 2010 .09 Acquisition of Microbiochips (by partial transfer of assets of MBC to BSI) ACQ+ [5 years]
BioSystems International 2010 .02 Partnering distribution agreement to Microbiochips for the commercialization of PlasmaScan antibody microarray products that speed-up identification of human plasma biomarkers MKTG [5 years]
BioSystems International 2009 .06 Licensing-out of BSI's patented monoclonal antibody proteomics platform to Lohocla Research Corporation for the discovery of novel alcoholism liver disease biomarkers in blood LICOUT [4 years]
BioSystems International 2008 .10 2nd round-financing : 3.5 M€ led by SGAM AI, with undisclosed private investors in order to foster R&D of lung, colon and breast cancer diagnostics to be marketed in 2010 RFINB [3 years]
BioSystems International 2007 .03 Nomination : Jean-Pierre Tirouflet as CEO, replacing co-founder ORGN [2 years]
BioSystems International 2006 .03 Partnering research agreement with AstraZeneca on arthrosis biomarkers R&D [1 year]
BioSystems International 2005 .01 1st round-financing : 3.0 M€, by Société Générale A.M. RFINA [0 year]
BioSystems International 2004 .05 Company founded by Laszlo Takacs, Andras Guttman, Barry L. Karger, William S. Hancock, as a spin-off from Pfizer France R&D center of Fresnes (Parke Davis Jouveinal), with name shortened as BSI ORGF [0 year]
BMSystems (Bio-Modeling) 2009 .06 Launch of BioXplain, the first open platform for Iterative, Predictive and Integrative Biology, with BioXpr (Belgium) and Kayentis (electronic pen) MKTG [4 years]
BMSystems (Bio-Modeling) 2008 .09 Patent : application, with CEA life Sciences, covering new therapeutic strategies and a preclinical evaluation platform for psychiatric disorders LEGAL [4 years]
BMSystems (Bio-Modeling) 2006 .12 Spin-off of Pherecydes (keeping minority equity) ACQ- [2 years]
BMSystems (Bio-Modeling) 2004 .08 Company founded by Manuel Géa, François Iris, Gérard Dine, Paul-Henri Lampe, Pablo Santamaria ORGF [0 year]
Carmatlégende 2011 .08 Public offering : 29.3 M€ (existing shareholders with preferred rights, oversubscribed at 127.4%) PBO [3 years]
Carmat 2010 .11 Research : assembly of the first clinical version of its artificial heart (clinical trial scheduled in 2011) R&D [2 years]
Carmat 2010 .07 Listing on Alternext Paris : 16.0 M€ PBO [2 years]
Carmat 2009 .10 Production : inauguration of cleanroom facilities in Vélizy INDUS [1 year]
Carmat 2009 .09 Nomination : Marcello Conviti, new CEO, replacing Patrick Coulombier (COO) ORGN [1 year]
Carmat 2009 .06 Financing (no interest loan) : 33.0 M€, by OSEO Innovation, to support 5 year-development plans DEBT [1 year]
Carmat 2009 .05 Company move from Suresnes to Vélizy (both, near Paris) ORGL [0 year]
Carmat 2008 .11 1st round-financing : 7.5 M€, by Truffle Capital, EADS, and Prof. Carpentier's foundation RFINA [0 year]
Carmat 2008 .10 Company founded by Alain Carpentier, with financial support by Oseo, based on a long collaboration between the renowned surgeon and EADS on implementation of biomaterials and cutting-edge technologies in the construction of an artificial heart ORGF [0 year]
Cellectis 2012 .10 Partnering research agreement with National Institutes of Health (NIH, USA) and several government agencies on iPS cells, with a maximum order of services of US$ 6.9 Million over 3 years R&D [12 years]
Cellectis 2011 .12 Partnering research agreement with Novartis licensing-out a patent enabling to introduce new characteristics into genomes R&D [11 years]
Cellectis 2011 .09 Acquisition of Cellartis, the European leader in stem cell-derived in vitro R&D tools, for 16.4 M€ and 1.93 Million Cellectis shares ACQ+ [11 years]
Cellectis 2011 .08 Financing : fund raising subscribed by FSI and Pierre Bastid, for 50 M€ (redeemed into shares in February 2012) RFIN [11 years]
Cellectis 2011 .05 Licensing-out of genome customization solutions to Wako in Japan LICOUT [11 years]
Cellectis 2011 .04 Financing : CDC invest 6 M€ (on 12 M€ capital increase) in subsidiary Ectycell to industrially develop iPS stem cells RFIN [11 years]
Cellectis 2011 .03 Launch of StemRed, a program to produce red blood cells from stem cells, with public institution EFS (Etablissement Français du Sang) MKTG [11 years]
Cellectis 2010 .10 Set-up of US subsidiary in Cambridge, Massachussetts (Cellectis bioresearch) ORGC [10 years]
Cellectis 2010 .09 Acquisition of total assets of Cyto Pulse (USA) for US$ 2.2 Millions in cash ACQ+ [10 years]
Cellectis 2010 .03 Licensing-out of use of homologous recombination patents to Boehringer Ingelheim in order to obtain, breed and utilize animal models LICOUT [10 years]
Cellectis 2010 .01 Licensing-out of use of homologous recombination patents to Bayer HealthCare aimed to introduce new features into the genome LICOUT [10 years]
Cellectis 2009 .10 Public offering (2nd) on Euronext : 22.0 M€ (1.914 Million new shares at 11.50 € each) PBO [9 years]
Cellectis 2009 .10 Acquisition of Vectocell Technology from Diatos assets (bankrupt in May 2009), to accelerate therapeutic development programs ACQ+ [9 years]
Cellectis 2009 .09 Set-up of Ectycell, a subsidiary specialized in stem cells from adults ORGC [9 years]
Cellectis 2009 .06 Launch of cGPS Custom, new kits for targeted gene integration in native cell lines, by affiliate Cellectis BioResearch (later extended to human cell lines and in gene function studies) MKTG [9 years]
Cellectis 2008 .12 Launch of PI10.3, a new research kit for producing stable cell clones using gene targeting in just 4 weeks, by affiliate Cellectis BioResearch MKTG [8 years]
Cellectis 2008 .11 Research : publication in Nature Magazine on a Therapeutic Meganuclease to treat a severe skin inborn disease by the CNIO, the CRG and Cellectis R&D [8 years]
Cellectis 2008 .09 Financing agreement by AFM (French Muscular Dystrophy Association), 8.3 M€ granted over 5 years for research on 7 genes surgery of orphan diseases RFIN [8 years]
Cellectis 2008 .06 Court : legal dispute on patents against Shionogi LEGAL [8 years]
Cellectis 2008 .05 Set-up of 2 new subsidiaries in France, Cellectis Bioresearch and Cellectis Genome Surgery ORGC [8 years]
Cellectis 2007 .02 Listing on Euronext Paris : 21.2 M€ PBO [7 years]
Cellectis 2005 .06 3rd round-financing : 5.6 M€, by BankInvest, AGF P.E., Odyssée, Edmond de Rothschild (follow-up) RFINC [5 years]
Cellectis 2004 .04 Company move from Paris (Institut Pasteur) to Biocitech in Romainville ORGL [4 years]
Cellectis 2002 .05 2nd round-financing : 8.0 M€, by BankInvest, AGF PE, Odyssée, Edmond de Rothschild RFINB [2 years]
Cellectis 2000 .11 1st round-financing : 3.8 M€, by Kaminvest RFINA [0 year]
Cellectis 2000 .06 Licensing-in of 6 lead products from Institut Pasteur (spin-off with equity) LICIN [0 year]
Cellectis 2000 .01 Company founded by André Choulika and David Sourdive ORGF [0 year]
Cellial Technologies 2007 .12 Nomination : Sandrine Leman [Institut Pasteur], as CEO, replacing Yves Wendzinski ORGN [6 years]
Cellial Technologies 2002 .12 Nomination : Yves Wendzinski [Eng. ISEN] as CEO (also Chairman), replacing Michel Major ORGN [1 year]
Cellial Technologies 2002 .11 1st round-financing : 1.0 M€, by Finorpa, Nord Innovation, Innovam RFINA [1 year]
Cellial Technologies 2001 .01 Company founded by Prof. Romeo Cecchelli (Institut Pasteur Lille), within Eurasanté Bio-incubator ORGF [0 year]
CellProthera 2010 .02 Nomination : Xavier Lataste, new CEO ORGN [1 year]
CellProthera 2008 .06 Company founded by Philippe Hénon (Prof. University of Haute Alsace) ORGF [0 year]
CellVax 2007 .00 Certification : Eureka award on Oligoclonics INFO [5 years]
CellVax 2001 .06 Company founded by Ming Wei, 2 other biologists, Christian Schatz [Pharm.D.], Olivier-Noël Martin [ex-Sterilyo, founder], and Michel Crépin ORGF [0 year]
Cerenis Therapeutics 2011 .03 Clinical trial (phase II) for CER-001, in acute coronary syndrome (beginning) CLIN [6 years]
Cerenis Therapeutics 2010 .07 3rd round-financing : 40.0 M€, half by FSI, half by previous shareholders, Sofinnova Partners, HealthCap, Alta Partners et TVM Capital, EDF Ventures, Orbimed and Daiwa (completed in October by 10.0 M€ additional from Irdi-IXO and private investors) RFINC [6 years]
Cerenis Therapeutics 2010 .05 Clinical trial (phase I) for CER-001, a new drug for acute coronary syndrome (completed) CLIN [6 years]
Cerenis Therapeutics 2010 .06 Financing (no interest loan) : 10.7 M€ by OSEO Innovation, shared with Novasep, to finance the development of CER-001, an HDL-mimetic innovative drug DEBT [6 years]
Cerenis Therapeutics 2009 .02 Financing (no interest loan) : 2.5 M€ by OSEO Innovation, to finance ongoing clinical development of HDL-related products for the treatment of cardiovascular and metabolic diseases DEBT [4 years]
Cerenis Therapeutics 2008 .05 Clinical trial (phase I) for CER-002, a peroxisome proliferator-activated receptor (PPAR) delta specific agonist (completed) CLIN [4 years]
Cerenis Therapeutics 2006 .11 2nd round-financing : 42.0 M€, led by TVM Capital, with Orbimed and previous shareholders (53.5 MUS$) RFINB [2 years]
Cerenis Therapeutics 2005 .08 1st round-financing : 25.0 M€, by Sofinnova, HealthCap, Alta Partners, EDF Ventures, NIF Ventures RFINA [1 year]
Cerenis Therapeutics 2004 .05 Company founded by Jean-Louis Dasseux and William Brinkerhoff ORGF [0 year]
CliniGenetics 2001 .07 1st round-financing : 6.0 M€, by BankInvest, a Danish capital venture group RFINA [0 year]
CliniGenetics 2000 .10 Company founded by a group of cardiovascular research scientists ORGF [0 year]
Covalab 2003 .02 Round-financing : 2.0 M€, searched to finance internal growth (failed) RFIN [7 years]
Covalab 1995 .07 Company founded by Saïd El Alaoui and Vincent Thomas ORGF [0 year]
Cytheris 2012 .07 Registration : orphan Drug designation by EMA for CYT107 in the treatment of Progressive Multifocal Leucoencephalopathy (PML) MKTG [13 years]
Cytheris 2012 .06 Nomination : Damian Marron, as CEO (Michel Morre on leave) ORGN [13 years]
Cytheris 2011 .06 Partnering development project with ImmunID and Centre Léon Bérard (Lyon), named DivRescue for cancer management R&D [12 years]
Cytheris 2011 .05 Clinical trial (phase II) for recombinant IL-7 combined with Xeloda in treatment of metastatic breast cancer (beginning) CLIN [12 years]
Cytheris 2010 .11 Clinical trial (phase II) for recombinant IL-7 combined with anti-retrovirals Raltegravir and Maraviroc to attack the viral reservoir in HIV patients (beginning) CLIN [11 years]
Cytheris 2010 .07 3rd round-financing : 12.0 M€, by CDC Entreprises (on behalf of FSI), along with historical investors RFINC [11 years]
Cytheris 2010 .02 Patent : granted from U.S. office covering the preparation and uses of its Glycosylated Recombinant Human Interleukin-7 (CYT107) LEGAL [11 years]
Cytheris 2009 .06 Research : publication in Nature Medicine showing that combination of Interleukin-7 with viral vaccine boosts immunity to tumors R&D [10 years]
Cytheris 2009 .03 Clinical trial (phase IIa) for recombinant IL-7 (completed), which induces a dramatic and prolonged CD4 and CD8 T cell expansion, sustained for 48 weeks in HIV patients CLIN [10 years]
Cytheris 2008 .07 Financing (no interest loan) : 1.5 M€, by OSEO, to support its ongoing clinical development program in hepatitis C (HCV) DEBT [9 years]
Cytheris 2007 .02 Clinical trial (phase I) for recombinant IL-7 (beginning) CLIN [8 years]
Cytheris 2006 .10 2nd round-financing : 24.3 M€, by CDC Innovation with ABN AMRO Capital Life Sciences (today, Forbion) and previous shareholders RFINB [7 years]
Cytheris 2005 .05 Licensing-in of a new immuno-modulating agent for HIV from New York University LICIN [6 years]
Cytheris 2003 .00 Set-up of US subsidiary in Rockville, Maryland ORGC [3 years]
Cytheris 2002 .07 1st round-financing : 7.0 M€, by Bioam with two Canadian funds, GestionT2C2/Bio and CDP Capital Technology Ventures, plus AXA P.E. and Crédit Agricole P.E. RFINA [3 years]
Cytheris 1999 .04 Licensing-in of Interleukin-7 (IL-7) from Sanofi-Aventis LICIN [0 year]
Cytheris 1999 .01 Company founded by Michel Morre (CEO), as Biotech Inflection Point ORGF [0 year]
Cytoo 2011 .12 Financing (grant) : 4.0 M€ (in part), by EU FP7 to launch Mehtrics, a public-private consortium, with Cenix BioScience and academic collaborators, to further develop high throughput and high content RNAi screening through convergence with micropatterning-based cell assays RFIN [3 years]
Cytoo 2011 .11 2nd round-financing : 7.0 M€, led by Sham and Entrepreneurs Fund (EF) and previous shareholders (Auriga and Jacques Lewiner) RFINB [3 years]
Cytoo 2010 .11 Launch of Cytooplates, for High Content Screening (HCS) MKTG [2 years]
Cytoo 2009 .09 Set-up of Cytoo Inc., US subsidiary (Boston) ORGC [1 year]
Cytoo 2009 .07 1st round-financing : 3.2 M€ by Auriga Partners and private investor RFINA [1 year]
Cytoo 2009 .04 Launch of Cytoochips, following worldwide exclusivity for adhesive cell micropattern technology from Curie Institute and CNRS (3 patents licensed-in), with on-line trading MKTG [0 year]
Cytoo 2009 .01 Company move to Miniatec (still in Grenoble), with 300 square meters facility RELOC [0 year]
Cytoo 2008 .10 Seed financing : 1.0 M€, by CEA Valorisation, Rhône-Alpes-Création, Expansinvest and private investors (undisclosed) SFIN [0 year]
Cytoo 2008 .06 Company founded by François Chatelain, Alexandra Fuchs, Jacques Lewiner, Michel Bornens ORGF [0 year]
DBVTechnologieslégende 2012 .10 Partnering research agreement with CIML (Centre d'Immunologie de Marseille-Luminy) on allergy mechanisms R&D [10 years]
DBV Technologies 2012 .08 Clinical trial (phase Iib, Vipes) for Viaskin Peanut in USA CLIN [10 years]
DBV Technologies 2012 .03 Listing on Euronext : 40.5 M€ (IPO) PBO [10 years]
DBV Technologies 2012 .02 Registration : FDA accepts Fast Track Designation status for Viaskin Peanut MKTG [9 years]
DBV Technologies 2011 .01 4th round-financing : 19.4 M€, including new investors InnoBio, Lundbeckfond Ventures, Shire plc, and Alto Invest, as well as existing investors Sofinnova Partners and ALK Abello RFIND [8 years]
DBV Technologies 2010 .09 Patent : granted on Viaskin Allergen Delivery System, in USA LEGAL [8 years]
DBV Technologies 2010 .03 Nomination : Pierre-Henri Benhamou, new CEO (still CSO, research director), replacing Jean-François Biry ORGN [8 years]
DBV Technologies 2009 .09 Clinical trial (phase IIa) for Viaskin Peanut (selected by NIH and US consortium) CLIN [7 years]
DBV Technologies 2009 .09 Licensing-out of milk allergy test to Laboratoires Bioprojet for France LICOUT [7 years]
DBV Technologies 2009 .01 3rd round-financing : 6 M€, by Sofinnova Partners, ALK-Abello (Pharma company) RFINC [6 years]
DBV Technologies 2007 .11 Licensing-out of milk allergy test to Numico (today Danone) LICOUT [5 years]
DBV Technologies 2006 .01 2nd round-financing : 12.3 M€, by Sofinnova Partners and Apax Partners RFINB [3 years]
DBV Technologies 2003 .00 1st round-financing : 1.0 M€, by Cap Décisif and Créagro RFINA [0 year]
DBV Technologies 2002 .11 Company founded by Pierre-Henri Benhamou and Bertrand Dupont, with funding from ANVAR, based on new technology led by Prof. Christophe Dupont (AP-HP, Cochin Hospital) ORGF [0 year]
Diaxonhit 2012 .12 Acquisition of Ingen, the leading independent distributor of in-vitro diagnostics in the French market with global company's name change from Exonhit to Diaxonhit ACQ+ [15 years]
Diaxonhit 2012 .11 Round-financing : 4.4 M€ through private investors (new shares) RFIN [15 years]
Diaxonhit 2012 .07 Clinical assessment completed for AclarusDx, a blood test that detects Alzheimer's disease specific biomarkers, in France and USA CLIN [14 years]
Diaxonhit 2011 .10 Partnering R&D agreement with Pfizer to identify Alzheimer’s disease biomarkers R&D [13 years]
Diaxonhit 2011 .03 Clinical validation for EHT Dx14 (first phase), a new transcriptomic signature allowing to differentiate, at molecular level, benign breast tumors from malignant tumors CLIN [13 years]
Diaxonhit 2010 .06 Round-financing : 1.43 M€ through TEPA-induced private investors RFIN [12 years]
Diaxonhit 2010 .04 Acquisition of oncology-focused RedPath Integrated Pathology (USA) to accelerate growth in molecular diagnostics (total : US$ 32 Millions), which has been mutually terminated in October 2010 ACQ+ [12 years]
Diaxonhit 2010 .03 Licensing-out to Allergan and BMS of EHT/AGN001 (a compound already in long term contract with Allergan), with upfront payment of 4 MUS$ LICOUT [12 years]
Diaxonhit 2009 .12 Public offering (4th) on Alternext : 15.6 M€ PBO [12 years]
Diaxonhit 2009 .11 Launch of AclarusDx, first diagnostic test in Alzheimer available as a Research Use Only product for Pharma industry (first step) MKTG [12 years]
Diaxonhit 2009 .09 Clinical trial (phase IIa) for EHT 0202 in Alzheimer's disease (completed) CLIN [11 years]
Diaxonhit 2009 .07 Round-financing : 1.45 M€ through the exercise of warrant with existing investors RFIN [11 years]
Diaxonhit 2009 .03 Proof-of-concept for SpliceArray platform for cancer diagnostic, evidence by I.G.R. (publication in Lancet Oncology) R&D [11 years]
Diaxonhit 2008 .06 Nomination : Loïc Maurel, as CEO ORGN [10 years]
Diaxonhit 2008 .04 Nomination : Philippe Rousseau as interim CEO after founders' resignation ORGN [10 years]
Diaxonhit 2007 .06 Public offering (3rd) on Alternext : 3.4 M€ PBO [9 years]
Diaxonhit 2006 .11 5th round-financing : 13.5 M€, in convertible bonds RFINE [9 years]
Diaxonhit 2006 .04 Public offering (2nd) on Alternext : 6.5 M€ PBO [8 years]
Diaxonhit 2005 .11 Listing on Alternext : 7.3 M€ PBO [8 years]
Diaxonhit 2004 .02 4th round-financing : 8.3 M€ in convertible bonds RFIND [6 years]
Diaxonhit 2001 .12 Licensing-out to Biomérieux (diagnostics) LICOUT [4 years]
Diaxonhit 2001 .12 3rd round-financing : 30.0 M€, by Dresdner Kleinwort, Danske Bank, LCF E. de Rothschild, Sudinnova, and previous shareholders RFINC [4 years]
Diaxonhit 2001 .11 Licensing-out to Allergan (drugs) LICOUT [4 years]
Diaxonhit 2001 .01 Set-up of US subsidiary in Maryland ORGC [3 years]
Diaxonhit 2000 .09 2nd round-financing : 14.0 M€, by AGF P.E. and BNP P.E. RFINB [2 years]
Diaxonhit 1998 .06 1st round-financing : 3.7 M€, by CDC Innovation, Sofinnova, Oxford Bioscience Partners (also, 0.8 M€, by ANVAR) RFINA [0 year]
Diaxonhit 1997 .11 Company founded by Bruno Tocqué [ex-Rhône Poulenc Rorer], Laurent Bracco [ex-RPR], Fabien Schweighoffer [ex-RPR] ORGF [0 year]
DNA Therapeutics 2011 .08 Clinical trial (phase I) for DT01 in cutaneous tumors (beginning, first dose completed in January, second dose in March) CLIN [5 years]
DNA Therapeutics 2011 .05 Financing (convertible bridge loan) : 2.0 M€, by OSEO, to support Dbait initial clinical trials DEBT [4 years]
DNA Therapeutics 2010 .10 Financing (grant) : 0.77 M€, by ANR, early stage clinical development of DT01 RFIN [4 years]
DNA Therapeutics 2010 .01 Patent (2nd) : granted on siDNA by USPTO (further secures the development of its lead product Dbait), followed 1 month later by European Patent Office (EPO), then China in 2011 LEGAL [3 years]
DNA Therapeutics 2009 .07 Financing (no interest loan) : 0.55 M€, by OSEO, to support CMC development of Dbait DEBT [3 years]
DNA Therapeutics 2009 .02 Research : publication in Clinical Cancer Research on Small-molecular drugs mimicking DNA damage (Dbait): a new strategy for sensitizing tumors to radiotherapy R&D [2 years]
DNA Therapeutics 2009 .01 1st round-financing : 2.2 M€, led by SGAM SEFTI with 2 previous seed investors, Blue Medical Investments and G1J-Île de France RFINA [2 years]
DNA Therapeutics 2008 .09 Seed financing : 0.8 M€, led by Inserm Transfer Initiative, with G1J-Île de France, Blue Medical Investment Group and International Business Angels (parallely to a patent granted on SiDNA) SFIN [2 years]
DNA Therapeutics 2007 .05 Patent : granted on siDNA by USPTA (secures the development of its lead product Dbait) LEGAL [0 year]
DNA Therapeutics 2006 .05 Company founded by Prof. Jian Sheg Sun, from concepts elaborated by Jean-Marc Cosset and Marie Dutreix, in 2001 ORGF [0 year]
Domain Therapeutics 2011 .01 Partnering development agreement with Merck Serono for Parkinson’s Disease and other neurodegenerative diseases R&D [9 years]
Domain Therapeutics 2009 .11 Research : successful completion of the first milestone in its Research Agreement with Takeda Pharmaceutical R&D [8 years]
Domain Therapeutics 2008 .12 4th round-financing : 2.1 M€ by historical investors (AGF Private Equity, Auriga Partners, Edmond de Rothschild Investment Partners and Sofinnova Partners), followed by Airfi (Alsace Inter Regio Fonds d'Investissement) and Alsace Création, plus Sam Eletr and Bernard Gilly RFIND [7 years]
Domain Therapeutics 2008 .12 Company renamed as Domain Therapeutics (from Faust Pharmaceuticals), with Bernard Gilly as President ORGF [7 years]
Domain Therapeutics 2008 .01 Partnering research agreement with Takeda R&D [6 years]
Domain Therapeutics 2006 .10 3rd round-financing : 8.2 M€, by previous shareholders (bridge financing) RFINC [5 years]
Domain Therapeutics 2006 .02 Nomination : Thomas Seoh as CEO, taking over from founders ORGN [4 years]
Domain Therapeutics 2004 .12 Clinical trial (phase IIa) for FP0011 in ALS and Parkinson's disease (beginning) CLIN [3 years]
Domain Therapeutics 2004 .04 2nd round-financing : 16.0 M€, by La Compagnie Financière Ed. de Rothschild, Siparex, AGF P.E., FCJE, and previous investors RFINB [2 years]
Domain Therapeutics 2003 .12 Acquisition of Euroclide, with a target oriented technology platform ACQ+ [2 years]
Domain Therapeutics 2003 .03 Company move from Paris to Strasbourg, in the BioValley cluster ORGL [1 year]
Domain Therapeutics 2002 .02 1st round-financing : 3.0 M€, by Sofinnova Partners and Auriga Partners RFINA [0 year]
Domain Therapeutics 2001 .10 Company founded as Faust Pharmaceuticals by Maurice Israël, Pierre Potier (Taxotere innovator), Pascal Neuville, based in Paris ORGF [0 year]
Dynabio 1998 .12 Nomination : new Board President, Yann Dagorn (born 1977) ORGN [6 years]
Dynabio 1992 .07 Company founded by unknown entrepreneurs ORGF [0 year]
Edelris 2010 .09 Partnering research agreement with Merck Serono in Fragment Based drug discovery R&D [5 years]
Edelris 2008 .04 Partnering research agreement with Roche to provide new compounds services for early stage R&D [3 years]
Edelris 2005 .02 Company founded by Jean-Yves Ortholand, Alfred Greiner, Claude Lardy, Catherine Vidal, Didier Roche, from a R&D activity in Merck Lipha Santé ORGF [0 year]
Endotis Pharma 2011 .06 Clinical trial (phase IIa) for EP217609, for use in open-heart surgery (beginning) CLIN [8 years]
Endotis Pharma 2010 .04 Clinical trial (phase I) for EP217609, a neutralizable anticoagulant, and its antidote avidin under development for use in heart surgery (completed) CLIN [7 years]
Endotis Pharma 2009 .05 Clinical trial (phase I) for EP42675, a first in class synthetic parenteral anticoagulant (completed, positive) CLIN [6 years]
Endotis Pharma 2008 .01 2nd round-financing : 25.0 M€, by the Wellcome Trust RFINB [4 years]
Endotis Pharma 2007 .11 Licensing-out of anti-thrombotics to Akzo Nobel LICOUT [4 years]
Endotis Pharma 2007 .06 Nomination : Charles Woller, new CEO, replacing David Béchard ORGN [4 years]
Endotis Pharma 2005 .07 1st round-financing : 9.0 M€, by Sofinnova C.V. and others RFINA [2 years]
Endotis Pharma 2003 .02 Company founded by David Béchard (CEO) [Ph.D. oncology, ex-OC&C], Philippe Lassalle [M.D., ex-Roche, Inserm], Franck Vivet [ex-Aventis, Baxter, Fournier] ORGF [0 year]
Epixis 2009 .09 Website under construction since May 2008 INFO [6 years]
Epixis 2003 .07 Company founded by Prof. David Klatzmann [AP-HP], Prof. François-Loïc Cosset [Inserm], Frédéric Tanguy [Institut Pasteur] ORGF [0 year]
ERYtech Pharma 2013 .03 Registration : FDA IND allowance for beginning Phase I with Grespa (USA traded as Eryasp) MKTG [8 years]
ERYtech Pharma 2012 .08 Nomination : Gil Beyen, new CEO, Pierre-Olivier Goineau, co-founder, moved to delegate general manager ORGN [7 years]
ERYtech Pharma 2012 .07 Registration : orphan Drug designation by EMA for investigational product Enhoxy for sickle cell disease MKTG [7 years]
ERYtech Pharma 2012 .06 Financing (no interest loan) : 6.95 M€, by OSEO, to lead the TEDAC project (Therapeutic Enzymes to Deplete Amino acids to treat Cancers resistant to radio/chemotherapy), within consortium including Exonhit, InGen BioSciences, AP-HP, Inserm and Paris-Diderot University DEBT [7 years]
ERYtech Pharma 2011 .05 Partnering distribution agreement with Teva on encapsulated drugs in red cells MKTG [6 years]
ERYtech Pharma 2010 .10 Partnering R&D agreement with Genzyme on novel therapeutic enzyme formulation R&D [5 years]
ERYtech Pharma 2010 .01 Registration : orphan Drug designation by FDA for GRASPA MKTG [5 years]
ERYtech Pharma 2009 .01 Partnering R&D agreement with American Red Cross to produce Graspa for clinical trials in USA R&D [4 years]
ERYtech Pharma 2008 .10 Clinical trial (phase II) for new vaccine concept against cancer, based on red blood cells, Vaccin'ERY (completed, positive) CLIN [3 years]
ERYtech Pharma 2008 .05 Clinical trial (phase II) for Graspa (orphan drug) in leukemia (completed) CLIN [3 years]
ERYtech Pharma 2006 .11 1st round-financing : 12.0 M€, by AXA P.E., Auriga Partners, AGF P.E., Capdecisif RFINA [2 years]
ERYtech Pharma 2006 .06 Registration : orphan Drug designation by EMEA for GRASPA MKTG [1 year]
ERYtech Pharma 2005 .11 Clinical trial (phase II) for lead compound in leukemia (beginning) CLIN [1 year]
ERYtech Pharma 2005 .10 Seed financing : 0.75 M€, by Amorçage Rhône Alpes (+ 0.45 M€ from contest by French Ministry of R&D) SFIN [0 year]
ERYtech Pharma 2004 .11 Company founded by Yann Godfrin and Pierre-Olivier Goineau ORGF [0 year]
Eye Tech Care 2012 .10 Launch of EyeOP1 device in Europe MKTG [4 years]
Eye Tech Care 2010 .07 2nd round-financing : 7.5 M€, by SHAM, Crédit Agricole, to finance clinical trials of EYEOP1 in glaucoma RFINB [2 years]
Eye Tech Care 2008 .12 1st round-financing : 1.2 M€, equally by Crédit Agricole and CEA Valorisation RFINA [0 year]
Eye Tech Care 2008 .07 Company founded by Fabrizio Romano, Philippe Chapuis [born 1968, Eng., ex-EDAP], and Laurent Farcy [Ms.Sc.], based on a platform developed at Inserm 556 unit by Jean-Yves Chapelon and incubated with Crealys ORGF [0 year]
FlamelTechnologieslégende 2012 .04 Nomination : Michael S. Anderson as CEO (ex-CEO of acquired Éclat), replacing Stephen H. Willard ORGN [21 years]
Flamel Technologies 2012 .03 Acquisition of Éclat Pharmaceuticals (USA),incorporated in Flammel US inc. ACQ+ [21 years]
Flamel Technologies 2011 .11 Supply Agreement with GlaxoSmithKline for Coreg CR Microparticles, using Flamel's Micropump technology, with upfront payment of 1.2 M€ MKTG [21 years]
Flamel Technologies 2011 .10 Partnering R&D agreement with Eagle Pharmaceuticals (USA) on Medusa-based hydrogel depot formulation for Eagle's small molecule antibiotic, tigecycline R&D [21 years]
Flamel Technologies 2011 .06 Partnering research agreement with Digna Biotech (Spain) for multiple products R&D [20 years]
Flamel Technologies 2011 .04 Licensing-out of Micropump to an undisclosed company, for pain management, with upfront payment of 3 M€ LICOUT [20 years]
Flamel Technologies 2010 .10 Partnering research agreement with Merck Serono for an extended release formulation of interferon beta-1a using the Medusa platform R&D [20 years]
Flamel Technologies 2009 .12 Clinical trial (phase IIa) of IFN-Alpha-2b XL in Patients with Chronic Hepatitis C Virus Infection (beginning) CLIN [19 years]
Flamel Technologies 2009 .07 Partnering research agreement with Baxter to formulate Longer Acting Forms of Blood Clotting Factors R&D [18 years]
Flamel Technologies 2009 .03 Financing : € 2.9 Millions ($4 Million) from GlaxoSmithKline (GSK) as a milestone pursuant to the Micropump license agreement for Coreg CR RFIN [18 years]
Flamel Technologies 2007 .12 Partnering research agreement with Merck Serono R&D [17 years]
Flamel Technologies 2006 .10 Registration : FDA approval of Coreg (carvedilol S.R), licensed to GSK MKTG [16 years]
Flamel Technologies 2005 .06 Nomination : Stephen H. Willard as CEO (from CFO in 2000), replacing founder Gérard Soula, after a coup by hedge funds ORGN [14 years]
Flamel Technologies 2003 .11 Licensing-out of Basulin to BMS, with upfront payment of 18 M€ (20.0 MUS$) LICOUT [13 years]
Flamel Technologies 2003 .10 Public offering (Nasdaq) : 56 M€ (62.1 MUS$) PBO [13 years]
Flamel Technologies 2002 .07 Licensing-out of Augmentin delivery-improved to GSK, with upfront payment of 1.3 M€ LICOUT [11 years]
Flamel Technologies 2000 .03 Round-financing : 12.8 M€, by Biotechnology Value Fund, Alta Biopharma, Chase Capital Partners RFIN [9 years]
Flamel Technologies 1999 .12 Licensing-out of Basulin to Novo Nordisk, with upfront payment of 5 M€ and milestones of 37 M€ (rights re-acquired in 2002) LICOUT [9 years]
Flamel Technologies 1996 .12 Listing on Nasdaq : 30 MUS$ (about 23.7 M€) PBO [6 years]
Flamel Technologies 1990 .08 Company founded by Gérard Soula [CEO, ex-Rhône Poulenc R&D], Jean Deléage [Alta Partners, as CEO, Supélec, died in 2011] ORGF [0 year]
Fluofarma 2011 .05 Research : publication in American Journal of Pathology on tissue microarray cytometry R&D [7 years]
Fluofarma 2009 .10 Partnering research agreement with Roche on innovative cell based assays and computational models R&D [5 years]
Fluofarma 2009 .07 Research : publication in Cell Research on outer membrane VDAC1 for permeability transition of the inner mitochondrial membrane R&D [5 years]
Fluofarma 2009 .03 Research : publication in New York Academy of Sciences on new glucocorticoid receptor antagonist with Organon (Schering-Plough, today merged with M.S.D) R&D [5 years]
Fluofarma 2008 .10 Research : publication in Cell Science on Bax redistribution during apoptosis R&D [4 years]
Fluofarma 2003 .11 Company founded by Pier Vincenzo Piazza, François Ichas, Francesca De Giorgi (all 3 Inserm researchers), and Jean-Baptiste Pin, as a spin-off from the European Institute of Chemistry and Biology (IECB) in Bordeaux, France ORGF [0 year]
GemacBiolégende 2008 .01 Company move from Cenon (Bordeaux eastern suburb) to Berganton, Saint Jean d'Illac, Southwest of Bordeaux ORGL [8 years]
GemacBio 2006 .03 Clinical trial (phase IIa) in Multiple Sclerosis diagnostic (completed) CLIN [6 years]
GemacBio 1999 .12 Company founded by Michel Geffard ORGF [0 year]
Genepep 2012 .06 Partnering research agreement with Servier (extended) R&D [9 years]
Genepep 2012 .01 Company move from Prades le Lez to St Jean de Védas (also near Montpellier) with new R&D facilities ORGL [8 years]
Genepep 2006 .03 Partnering research agreement with Skuld-tech R&D [3 years]
Genepep 2003 .03 Company founded by Karine Puget and Jean Martinez (a therapeutic peptide specialist), incubated in the faculty of Pharmacy of Montpellier ORGF [0 year]
Genewave 2010 .01 Company headquarters move from Palaiseau (near Paris) to Paris with R&D facilities in Genopole Evry ORGL [8 years]
Genewave 2009 .06 Financing (no interest loan) : 9.0 M€, by OSEO Innovation, for the NOSOBIO program for prevention, diagnostics and treatment of hospital-acquired infections (with Serial Genetics, Palumed, Da Volterra, Institut Pasteur and Assistance Publique-Hôpitaux de Paris) DEBT [7 years]
Genewave 2008 .05 Launch of HybLive, first real-time micro-array platform MKTG [6 years]
Genewave 2008 .01 Nomination : François X. Desforges as President and Houtaï Choumane as CEO ORGN [6 years]
Genewave 2001 .12 Company founded by Claude Weisbuch (CEO), François Vallet and others ORGF [0 year]
Genfit 2013 .04 Financing (new shares) : 14.0 M€ in private placement, to enhance development programs (GFT505, in phase IIb, TGFTX1 and TGFTX3) RFIN [13 years]
Genfit 2012 .10 Financing (new shares) : 2.0 M€ in convertible bonds, all being converted into new shares by YA Global Master, one of the historical shareholders RFIN [13 years]
Genfit 2012 .05 Clinical trial (phase IIa) in GFT505 with a dose three-fold higher in obese subjects (followed by the beginning of an FDA phase IIb study in September) CLIN [12 years]
Genfit 2012 .04 Financing (new shares) : 0.6 M€, by YA Global Master, as a private placement reserved to one of the historical shareholders (also 0.5 M€ in July to an undisclosed historical shareholder) RFIN [12 years]
Genfit 2011 .11 Financing (new shares) : 0.5 M€, by University Lille II (France), as a private placement reserved to one of the historical shareholders RFIN [12 years]
Genfit 2011 .08 Financing (new shares) : 5.3 M€, by YA Global Master (Yorkville Advisors) and 5.1 M€ by existing shareholders, for GFT505 further development (increased by 0.1 M€ in November, again with Yorkville) RFIN [11 years]
Genfit 2011 .07 Clinical trial (phase IIa) in NAFLD/NASH and the prevention of cardiovascular risk in diabetic patients (completed, positive) CLIN [11 years]
Genfit 2011 .03 Partnering research agreement with Sanofi-Aventis for new drugs for the treatment of metabolic disorders (undisclosed annual payments and milestone payments up to 39 M€ according to R&D progress) R&D [11 years]
Genfit 2010 .12 Financing (funding) : 1.2 M€ (as part of the EuroTransBio funding initiative), for the OLNORME (Occurrence of novel Ligands for a Nuclear Orphan Receptor in plant Metabolites) program RFIN [11 years]
Genfit 2010 .09 Clinical trial (phase I) for GFT505 on healthy volunteers showing it potentiates insulin action in humans (end), followed by the beginning of a phase II CLIN [11 years]
Genfit 2010 .07 Financing (no interest loan) : 2.3 M€, by OSEO, for early development DEBT [10 years]
Genfit 2010 .02 Financing (capital increase) : 2.3 M€ on Alternext PBO [10 years]
Genfit 2009 .11 Clinical trial (phase II) for GFT505 (end) in prediabetic patients with atherogenic dyslipidemia and abdominal obesity CLIN [10 years]
Genfit 2009 .03 Licensing-in by acquisition of the research program MKG02 focused on type 2 diabetes and obesity, from Merck Serono LICIN [9 years]
Genfit 2009 .02 Research : new theranostic strategy unveiled with an innovative biomarker technology dedicated to early detection of atherosclerosis R&D [9 years]
Genfit 2008 .06 Financing (no interest loan) : 7.1 M€, by Oseo for IT-Diab programme (drug and diag) with Genoway, SpiBio, Roowin and Academic Institutions, over 5 years DEBT [8 years]
Genfit 2008 .04 Management crisis : direct conflict between 2 co-founders, Jean-François Mouney, CEO and Jean-Charles Fruchart, President of Supervisory Board (dismissed) ORG [8 years]
Genfit 2006 .12 Listing on Alternext : 15.0 M€ PBO [7 years]
Genfit 2006 .05 Clinical trial (phase II) for first lead, GFT14 (beginning) CLIN [6 years]
Genfit 2003 .00 Set-up of international offices in Cambridge (USA) ORGC [3 years]
Genfit 2000 .03 Seed financing : 2 M€, by UCB, Aventis, Sanofi-Synthelabo, Merck-Lipha, Finorpa, Nord Création, BP Création SFIN [0 year]
Genfit 1999 .09 Company founded by Prof. Jean-Charles Fruchart (born 1945), Jean-François Mouney, Prof. Bart Staels, Florence Séjourné ORGF [0 year]
Genomic Vision 2012 .04 Launch of new diagnostic test for facio-scapulo-humeral dystrophy (FSHD), an orphan disease MKTG [7 years]
Genomic Vision 2011 .07 Partnering strategic agreement with Quest Diagnostics (USA) with cross licensing of new products in USA vs. Europe MKTG [7 years]
Genomic Vision 2010 .02 Financing (subsidy) : 0.25 M€ from AFM to develop a routine clinical test for FSHD (dystrophia) RFIN [5 years]
Genomic Vision 2008 .10 Financing (no interest loan) : 1.1 M€, by OSEO Innovation, on an antiviral programme (partnered with Cellectis, which gets 7.5 M€) DEBT [4 years]
Genomic Vision 2008 .07 2nd round-financing : 4.0 M€, by Vesalius BioCapital and previous shareholder Société Générale Asset Management Alternative Investments (SGAM AI) RFINB [4 years]
Genomic Vision 2005 .11 1st round-financing : 2.0 M€, by Société Générale Asset Management (SGAM) RFINA [1 year]
Genomic Vision 2004 .07 Company founded by Aaron Bensimon (board chairman, CEO) and Daniel Nerson (COO) ORGF [0 year]
GenoSafe 2010 .02 Nomination : Stéphane Roques as CEO, replacing Didier Caizergues ORGN [6 years]
GenoSafe 2008 .11 Nomination : Didier Caizergues as Board President and CEO, replacing Anne-Marie Masquelier ORGN [5 years]
GenoSafe 2006 .11 Financing : grant of 3.5 M€, by A2i (Oseo), coordinated by Mérieux Alliance, within ADNA project DEBT [3 years]
GenoSafe 2005 .06 Nomination : Anne-Marie Masquelier, as CEO (plus, President, in 2006) ORGN [1 year]
GenoSafe 2003 .09 Company founded by Genethon and AFM (Association Française pour les Myopathies, i.e. French Muscular Dystrophy Association) ORGF [0 year]
GenoScience Pharma 2006 .11 Acquisition of Genesodi, a bio-informatics venture ACQ+ [5 years]
GenoScience Pharma 2005 .00 Acquisition of a Patent from Inserm for the HCVpp test LEGAL [3 years]
GenoScience Pharma 2002 .00 Partnering research agreement with Gilead (USA) on HIV Tenofovir drug resistance R&D [0 year]
GenoScience Pharma 2001 .08 Company founded by Prof. Philippe Halfon ORGF [0 year]
Genoscreen 2012 .02 Partnering research agreement with public labs (19 teams in France, of which Institut Pasteur and CNRS) regarding Labex ParaFrap against parasitic infections R&D [11 years]
Genoscreen 2011 .02 Financing : grant of 8.0 M€, by Grand Emprunt National, for Equipex, a project of platform LIGAN equipment between Genoscreen and PRES-Lille Nord University to speed up R&D on Alzheimer disease (Genoscreen/Pasteur Lille), diabetes (CNRS UMR 8090) and some blood cancers (Lille 2/CHR) DEBT [10 years]
Genoscreen 2009 .04 Launch of new MIRU-VNTR typing kit for Mycobacterium tuberculosis complex (kits, training and software tool, based in client's premises) MKTG [8 years]
Genoscreen 2006 .00 Launch of new standardised MIRU-VNTR genotyping service for Mycobacterium tuberculosis (in-house based, from client's samples) MKTG [4 years]
Genoscreen 2001 .01 Company founded by André Tordeux, as a spin-off from Institut Pasteur (Lille) ORGF [0 year]
GenOway 2012 .04 Partnering distribution agreement for Internal Ribosome Entry Site (IRES) technology by StemCells to Genoway (exclusive worldwide licence) MKTG [13 years]
GenOway 2012 .03 Partnering distribution agreement for all services of animal model creation and phenotpying by Phenopro (ex-ICS) to Genoway (exclusive worldwide licence) MKTG [13 years]
GenOway 2011 .07 Licensing-in of RMCE technology from Bluebird Bio (USA) for genetically modified rodents LICIN [12 years]
GenOway 2010 .06 Partnering sales agreement with 3 major Japanese biopharmaceutical companies, as new customers MKTG [11 years]
GenOway 2010 .05 Partnering research agreement with Griffith University (Australia) for olfactory stem cells technology R&D [11 years]
GenOway 2009 .10 Licensing-in of Flex technology, developed by Prof. Pierre Chambon and Dr Norbert Ghyselinck at the IGBMC (Strasbourg) LICIN [10 years]
GenOway 2009 .02 Launch of StemCellHY, a new production technology including ThromboGenics' proprietary stem cell lines MKTG [9 years]
GenOway 2008 .06 Financing (no interest loan) : 7.1 M€, by Oseo for IT-Diab programme (drug and diag) with Genfit, SpiBio, Roowin and Academic Institutions, over 5 years DEBT [9 years]
GenOway 2007 .00 Partnering research agreement with Boehringer Ingelheim (USA) to provide murine models R&D [7 years]
GenOway 2007 .05 Seed financing : 1.1 M€, by NGFN (National Genome Research Network) in Germany SFIN [8 years]
GenOway 2007 .05 Listing on Alternext : 6.2 M€ (23% of shares) PBO [8 years]
GenOway 2006 .05 Partnering distribution agreement with Charles River (USA market, co-promotion) MKTG [7 years]
GenOway 2005 .00 Acquisition of Murinus (Germany) ACQ+ [5 years]
GenOway 2004 .09 2nd round-financing : 4.0 M€, led by CDC Entreprises, Siparex Ventures RFINB [5 years]
GenOway 2003 .04 1st round-financing : 3.5 M€, led by Dassault Developpement, with Qualis, Rhône Alpes Création RFINA [4 years]
GenOway 1999 .03 Company founded by Alexandre Fraichard and Gilles de Poncins, as a spin-off from Normale Sup (Lyon) ORGF [0 year]
Genticel 2012 .10 Clinical trial (phase Ib) for Procervix (redesigned) aimed at preventing cervical cancer in patients already infected by HPV (positive results on primary objective, safety and local tolerance, and secondary objective, antigen-specific cellular immunity) CLIN [11 years]
Genticel 2011 .10 Clinical trial (phase I) for Procervix (redesigned) aimed at preventing cervical cancer in patients already infected by HPV (recruitment completed) CLIN [10 years]
Genticel 2010 .07 Clinical trial (phase I) for Procervix (redesigned) aimed at preventing cervical cancer in patients already infected by HPV (beginning) CLIN [8 years]
Genticel 2010 .03 3rd round-financing : 13.1 M€, led by AGF Private Equity, with 3 new investors, IRDI (Institut Régional de Développement Industriel), Amundi Private Equity Funds and InnoBio fund, managed by CDC Entreprises, and previous investors, including Edmond de Rothschild Investment Partners (EdRIP) RFINC [8 years]
Genticel 2010 .02 Company name change from BT Pharma to Genticel INFO [8 years]
Genticel 2008 .09 2nd round-financing : 2.8 M€ mainly by Edmond de Rothschild Investment Partners, followed by Fonds d'Amorçage Midi-Pyrénées RFINB [6 years]
Genticel 2007 .09 Clinical trial (phase I) for Procervix, HPV vaccine (beginning) CLIN [5 years]
Genticel 2007 .05 1st round-financing : 1.3 M€, mainly by Institut Pasteur and an undisclosed private investor RFINA [5 years]
Genticel 2001 .10 Company founded by Benedikt Timmerman, as a spin-off from Institut Pasteur (Paris) ORGF [0 year]
GTP Technology 2012 .08 Partnering supply agreement with European Vaccine Initiative (EVI) and Inserm in the Primalvac project for the development of a pregnancy associated malaria (PAM) vaccine R&D [11 years]
GTP Technology 2011 .01 Nomination : Christopher Pease (also Managing dir. Darlington Life Science) as CEO, replacing Éric Devic, founder, new COO, also chairman ORGN [10 years]
GTP Technology 2010 .11 Partnering research agreement with Indicia to combine competencies for Ab-Ag R&D [10 years]
GTP Technology 2010 .04 Launch of catalogue of recombinant proteins for research, ready-to-use proteins and on demand proteins MKTG [9 years]
GTP Technology 2006 .06 Certification : approval by regional Cancer-Bio-Santé cluster of L. lactis research program INFO [5 years]
GTP Technology 2005 .04 Launch of Eiffel Biostructure platform with two partners, AliX and NMRtec, to extend services to structural analysis MKTG [4 years]
GTP Technology 2004 .12 Seed financing : 0.45 M€, by undisclosed investors SFIN [4 years]
GTP Technology 2003 .12 Partnering supply agreement with Pierre Fabre on recombinant protein R&D [3 years]
GTP Technology 2003 .01 Company move from Toulouse base to Labège (near Toulouse) ORGL [2 years]
GTP Technology 2000 .10 Company founded by Éric Devic, as a spin-off from the Protein Engineering Department of P. Sabatier University in Toulouse, France ORGF [0 year]
HeliosBioscienceslégende 2012 .01 Company move from Créteil Hospital center to Romainville, Biocitech (also, near Paris), still with some facilities in Créteil ORGL [9 years]
Helios Biosciences 2009 .00 Research : selection for validation of 3 of the 6 immunosuppressives targets with Immuno-Dyn, with peptides used to transfect lymphocytes R&D [6 years]
Helios Biosciences 2005 .06 Research : finalization of first large-scale dynamic model of human T-lymphocyte R&D [3 years]
Helios Biosciences 2002 .05 Company founded by Jean-Baptiste Dumas (CEO), with name shortened as HBS ORGF [0 year]
Hemarina 2012 .07 3nd round-financing : 6.3 M€, by Inserm Transfert Initiative, with Finistère Angels, Armor Angels, XMP and Arkéa Capital Investissement, to help bring to market its first product in the field of organ transplant RFINC [5 years]
Hemarina 2011 .11 Financing : grant of 0.7 M€, by ANR, for the HEMO2Perf project which involves the preclinical evaluation of HEMO2Life for the storage of kidney transplants in preservation solutions and machine perfusion systems RFIN [4 years]
Hemarina 2010 .07 2nd round-financing : 3.0 M€, by Inserm Transfert Initiative, Finistère Angels, Angels Santé, Armor Angels, XMP Business Angels, Synergie Finance, Vaneau RFINB [3 years]
Hemarina 2010 .03 Partnering marketing agreement on HemoxCell distribution in France by Abcys MKTG [3 years]
Hemarina 2007 .03 Company founded by Franck Zal, Morgane Rousselot, Gilles Avenard [born 1951, M.D., ex-Hoechst-Marion-Roussel, CNTS, BioAlliance], as a spin-off of CNRS and Pierre-et-Marie-Curie University ORGF [0 year]
Hybrigenics 2010 .09 Partnering research agreement with L'Oréal on protein interactions stydies beyond classical Yeast Two-Hybrid technology R&D [12 years]
Hybrigenics 2010 .09 Clinical trial (phase IIa) for inecalcitol (promising results) CLIN [12 years]
Hybrigenics 2010 .07 Set-up of Hybrigenics Services, a subsidiary servicing company dedicated to subcontracting activities ORGC [12 years]
Hybrigenics 2009 .12 Financing : 2.7 M€ issued for private investors, i.e. 10.5% capital, for inecalcitol development costs (in complement to Yorkville) RFIN [11 years]
Hybrigenics 2009 .09 Financing : up to 5 M€ through privileged new shares to Yorkville, over 3 years RFIN [11 years]
Hybrigenics 2009 .09 Partnering research agreement with yeast two-hybrid contract of 1.5 M€, for services to an American multinational life sciences company during 3 years R&D [11 years]
Hybrigenics 2009 .05 Set-up of Hybrigenics Services, a subsidiary owned by Rémi Delansorne ORGC [11 years]
Hybrigenics 2009 .02 Financing : 0.4 M€ by E.U. to participate in Masterswitch European project and screen inhibitors of protein interaction in the field of chronic inflammatory diseases RFIN [11 years]
Hybrigenics 2008 .12 Patent : granted on protease inhibitors specific to ubiquitin (cancer) LEGAL [10 years]
Hybrigenics 2008 .09 Financing (no interest loan) : 1.4 M€, by OSEO, to support its ongoing clinical development program of inecalcitol in prostate cancer DEBT [10 years]
Hybrigenics 2007 .12 Listing on Alternext : 6.2 M€ PBO [9 years]
Hybrigenics 2005 .09 Nomination : Rémi Delansorne, as CEO (previously CSO since 2004), replacing Donny Strosberg ORGN [7 years]
Hybrigenics 2003 .05 Acquisition of Semaia (Holland), a biotech focused on oncology ACQ+ [5 years]
Hybrigenics 2002 .04 3rd round-financing : 16.8 M€, led by Life Science Partners, with Banexi V.P., C.F. Edmond de Rothschild, and previous shareholders RFINC [4 years]
Hybrigenics 2000 .10 2nd round-financing : 19.5 M€, led by Alafi Capital, Lombard Odier, Medicis, Rendex, Sofindev, and previous shareholders RFINB [2 years]
Hybrigenics 1999 .06 1st round-financing : 9.1 M€, led by Auriga Partners, IMH, HealthCap, and previous shareholders RFINA [1 year]
Hybrigenics 1998 .05 Seed financing : 1 M€, by Apax Partners, Altamir SFIN [0 year]
Hybrigenics 1998 .04 Licensing-in of any discovery by Institut Pasteur on protein-protein interaction, with right of first refusal and exclusivity LICIN [0 year]
Hybrigenics 1998 .01 Company founded by Prof. Arthur Donny Strosberg (CEO), Pierre Legrain, Jacques Camonis, and Richard Benarous ORGF [0 year]
Hyphen BioMed 1999 .01 Company founded by Jean Amiral and Anne Marie Vissac, in the venture incubator of Conflans-Sainte-Honorine (near Paris) ORGF [0 year]
Imagenelégende 2011 .03 Candidate Partner in BioBanques project (supported by Inserm), based on its technology of preservation of DNA at room temperature R&D [12 years]
Imagene 2009 .05 Inauguration of new industrial platform in Evry for long-term DNA encapsulation INDUS [10 years]
Imagene 2006 .12 1st round-financing : 2.0 M€, by OTC A.M. and Aquitaine Création Investissement, to build a production facility RFINA [8 years]
Imagene 1998 .12 Company founded by a multi-disciplinary team of scientists, including Sophi Tuffet (CEO), with a world patent ORGF [0 year]
ImmunId 2011 .06 Partnering development project with Cytheris and Centre Léon Bérard (Lyon), named DivRescue for cancer management R&D [6 years]
ImmunId 2010 .10 Clinical trial (phase II interim) for ImmunTraCkeR and Immun'Ig in lymphoma and leukemia (beginning, RIPAL), with Prof. Gilles Salles (Lyon Hospital) CLIN [5 years]
ImmunId 2009 .11 Partnering development agreement with Roche Diagnostics to standardize immuno-monitoring in molecular biology R&D [4 years]
ImmunId 2009 .05 1st round-financing : 2.4 M€, by Vizille Capital Innovation (Vizille Capital Innovation & Sudinnova), SOFIMAC Partners and CEA Investissement RFINA [4 years]
ImmunId 2009 .05 Launch of Platine, a joint immuno-monitoring platform, by 5 partners (Innate Pharma, Transgene, ImmunID, Inserm and Cancer Centre Léon-Bérard), based in Lyon MKTG [4 years]
ImmunId 2008 .12 Financing (no interest loan) : 1.6 M€, by OSEO, to support its clinical development program of validation NDL biomarker and ImmunTraCkeR diagnostic test DEBT [3 years]
ImmunId 2008 .09 Licensing-in of a genomic analytical process from CEA and INSERM LICIN [3 years]
ImmunId 2008 .01 Partnering research agreement with Sanofi Pasteur R&D [2 years]
ImmunId 2007 .07 Certification : ISO 9001-2000 INFO [2 years]
ImmunId 2005 .03 Company founded by Nicolas Pasqual and Sébastien Weisbuch, for immunomonitoring and diagnostic solutions ORGF [0 year]
Immutep 2011 .01 Licensing-out to GlaxoSmithKline for IMP731, a novel therapeutic antibody for the treatment of autoimmune diseases (upfront payment and milestones of up to 75 M€) LICOUT [9 years]
Immutep 2009 .01 Clinical trial (phase II interim) for ImmuFact IMP321 associated with paclitaxel doubles clinical response rate in Metastatic Breast Cancer (confirmed in January 2010, with final results) CLIN [7 years]
Immutep 2008 .10 Registration : FDA IND allowance for IMP321 in Pancreatic Cancer MKTG [7 years]
Immutep 2005 .04 Clinical trial (phase II) for IMP321 (beginning) CLIN [3 years]
Immutep 2005 .01 2nd round-financing : 2.5 M€, by Innoven, for the lead compound IMP321 (immuno-stimulation factor) RFINB [3 years]
Immutep 2003 .12 1st round-financing : 2.5 M€, by FCPI La Poste Innovation, Innoven RFINA [2 years]
Immutep 2001 .09 Company founded by Prof. Frédéric Triebel and John B. Hawken, as a spin-off from Institut Gustave Roussy (the largest cancer center clinic in Europe, located South of Paris) and Serono (today Merck-Serono) ORGF [0 year]
Imstar 2010 .01 Partnering research agreement, Biotype, with Sanofi Aventis and 4 academic labs, CEA, Institut Pasteur, Armines and Assitance Publique-Hôpitaux de Paris (AP-HP), to develop new approaches in prostate cancer (completed after 30 months) R&D [24 years]
Imstar 2008 .10 Research : publication in Mutagenesis with validation of the automated scoring for Micronucleus assay using IMSTAR Pathfinder technology on human lymphocytes R&D [23 years]
Imstar 2008 .05 Partnering distribution agreement with Naturegene for China market MKTG [22 years]
Imstar 1997 .00 Launch of Pathfinder, for automated digital imaging MKTG [11 years]
Imstar 1985 .09 Company founded by Françoise Soussaline, as a spin-off from CEA ORGF [0 year]
In-Cell-Art 2012 .03 Financing (no interest loan) : 1.2 M€, by Oseo, to support a collaborative R&D program in the field of infectious diseases with nanocarrier technologies DEBT [6 years]
In-Cell-Art 2011 .12 Partnering R&D agreement with an undisclosed leading U.S firm operating in the field of diagnostic products to develop novel diagnostic antibodies using ICANtibodies R&D [6 years]
In-Cell-Art 2011 .01 Partnering distribution agreement with Wako for the Japanese commercialization of ICAFectin reagents MKTG [5 years]
In-Cell-Art 2010 .12 Partnering distribution agreement with Cosmo Bio for the Japanese distribution of ICANtibodies, a custom antibody production service MKTG [5 years]
In-Cell-Art 2010 .06 Partnering research agreement with OMT (Open Monoclonal Technology), to generate human monoclonal antibodies using its DNA immunization technology in OMT rats R&D [4 years]
In-Cell-Art 2008 .08 Partnering research agreement with Sanofi Pasteur, to evaluate Incellart technologies of nanocarriers R&D [3 years]
In-Cell-Art 2005 .08 Company founded by Prof. Jean-Marie Lehn (Nobel Prize), Prof. Pierre Lehn, Bruno Pitard ORGF [0 year]
Indicia Biotechnology 2011 .12 Licensing-in of the rights to exploit Immuno'line, a full range of services and patented technologies dedicated to Risk Assessment Immunogenicity, from Proteus LICIN [13 years]
Indicia Biotechnology 2010 .11 Partnering research agreement with GTP Technology to combine competencies for Ab-Ag R&D [12 years]
Indicia Biotechnology 2010 .05 Partnering research agreement with Singulex (USA) on biomarker quantification at the femtogram level to provide ultrasensitive and early biomarker detection through Erenna Immunoassay System R&D [11 years]
Indicia Biotechnology 2009 .09 Research : launch of Gliadys project, in collaboration with IDD Biotech, based on therapeutic antibodies against different glioma forms R&D [11 years]
Indicia Biotechnology 2008 .03 Acquisition of Axcell Biotech to strengthen OEM commercial position ACQ+ [9 years]
Indicia Biotechnology 1998 .07 Company founded by Stéphane Legastelois ORGF [0 year]
InGen Biosciences 2012 .07 Partnering distribution agreement with Quidel and Diagnostic Hybrids, to sell their in vitro diagnostics in France MKTG [10 years]
InGen Biosciences 2012 .06 Partnering services agreement with Eritech on project Tedac (translational medicine against cancer) R&D [10 years]
InGen Biosciences 2011 .12 Acquisition of Belgian biotech company Gamma with its Tetanos Quick Stick in vitro diagnostic (through ZenTech) ACQ+ [10 years]
InGen Biosciences 2010 .12 Nomination : Isabelle Buckle, new CEO, replacing Jean-Pierre Hermet (Board chairman) ORGN [9 years]
InGen Biosciences 2009 .03 Company rename as InGen Biosciences (from Abag) ORGL [7 years]
InGen Biosciences 2008 .12 Nomination : Jean-Pierre Hermet, new CEO ORGN [7 years]
InGen Biosciences 2006 .07 Acquisition of Ingen, a distribution company founded in 1993 ACQ+ [4 years]
InGen Biosciences 2006 .02 2nd round-financing : 6.0 M€, by new investor, Innoven (followed by Société Générale A.M.) RFINB [4 years]
InGen Biosciences 2003 .03 1st round-financing : 2.0 M€, by Société Générale A.M. RFINA [1 year]
InGen Biosciences 2001 .12 Company founded by Marc Bourlioux and Jean-Louis Gaillard, as AbAg ORGF [0 year]
Innate Pharma 2012 .10 Clinical trial (phase II, beginning) for monoclonal antibody IPH 2102, supported by Bristol Myers Squibb (with BMS-986015 as an anti-KIR antibody in combination with an anti-PD1 antibody in patients with advanced solid tumors) CLIN [13 years]
Innate Pharma 2012 .01 Research : publication in Science of discovery in the field of innate immunity, made by a team led by Prof. Eric Vivier, Innate Pharma's scientific co-founder at the Center of Immunology of Marseille-Luminy (CIML) R&D [12 years]
Innate Pharma 2011 .07 Licensing-out to Bristol-Myers Squibb of of IPH2102, a novel antibody in Phase I development for the treatment of cancer (upfront payment of 35 MUS$ plus milestones up to 430 MUS$) LICOUT [11 years]
Innate Pharma 2011 .05 Partnering development agreement with Transgene for immunomonitoring services, with set-up of new company named Platine Pharma Services R&D [11 years]
Innate Pharma 2009 .12 5th round-financing : 23.1 M€, by FSI (for 11 M€) and previous investors (Novo Nordisk and Alta Partners) RFINE [10 years]
Innate Pharma 2009 .09 Clinical trial (phase II) for IPH1101 in smoldering myeloma (beginning) CLIN [10 years]
Innate Pharma 2009 .08 Clinical trial (phase II, beginning) for monoclonal antibody IPH 2101, supported by 2.9 M€ financing from Oseo (results published in October 2012) CLIN [9 years]
Innate Pharma 2009 .06 Clinical trial (phase IIa, positive) for IPH1101 in type C Hepatitis CLIN [9 years]
Innate Pharma 2009 .05 Launch of Platine, a joint immuno-monitoring platform, by 5 partners (Innate Pharma, Transgene, ImmunID, Inserm and Cancer Centre Léon-Bérard), based in Lyon MKTG [9 years]
Innate Pharma 2009 .01 Partnering research agreement with Vivalis to produce IPH 4101 with EB66 for clinical trials (Oseo debt financing grant of 3.0 M€ for Innate Pharma) R&D [9 years]
Innate Pharma 2008 .04 Set-up of US subsidiary (operations) in New York State ORGC [8 years]
Innate Pharma 2008 .02 Set-up of 2 subsidiaries (trade, production) in France ORGC [8 years]
Innate Pharma 2007 .05 Nomination : Gilles Brisson, new Board Chairman, ex-Chairman Supervisory Board at Aventis Pharma France ORGN [7 years]
Innate Pharma 2007 .01 Launch of PGX Predict (diagnostics) by Clinical Data Inc., US partner MKTG [7 years]
Innate Pharma 2006 .11 Listing on Eurolist by Euronext Paris : 33.7 M€ PBO [7 years]
Innate Pharma 2006 .00 4th round-financing : 10.0 M€, by Novo Nordisk RFIND [6 years]
Innate Pharma 2006 .06 Licensing-in of lead compound (TLR) from Schering-Plough LICIN [6 years]
Innate Pharma 2006 .03 Licensing-out to Novo Nordisk (total of 15.0 M€ equity investment, including 2003 deal) LICOUT [6 years]
Innate Pharma 2004 .07 3nd round-financing : 15.0 M€, by Novo Nordisk, Quilvest and NIF Ventures RFINC [4 years]
Innate Pharma 2003 .11 Licensing-out to Novo Nordisk for the generation of a new therapeutic class of immuno-modulatory antibodies targeting natural killer (NK) cells LICOUT [4 years]
Innate Pharma 2002 .08 2nd round-financing : 20.0 M€, by Alta Partners and AXA P.E., with Gilde Biotech & Nutrition, Pechel Industries, Innoveris RFINB [2 years]
Innate Pharma 2002 .05 Clinical trial (phase I) for Innacell and Phosphotim (beginning) CLIN [2 years]
Innate Pharma 2002 .02 Financing (no interest loan) : 2.0 M€, by ANVAR, to support initial clinical trials DEBT [2 years]
Innate Pharma 2000 .04 1st round-financing : 4.5 M€, led by Sofinnova Partners, with Auriga Partners, GIMV RFINA [0 year]
Innate Pharma 1999 .10 Company founded by 4 European Scientists, pioneers in the field of innate immunity (Alessandro Moretta, Marc Bonneville, Jean-Jacques Fournier and Eric Vivier) and 2 managers from the biopharmaceutical industry (Hervé Brailly and François Romagné) ORGF [0 year]
InnaVirVax 2012 .03 Clinical trial (phase I/IIa) for VAC-3S, a novel immunotherapy for the treatment of HIV-1 infections (beginning), with a grant of 0.6 M€ from OSEO CLIN [4 years]
InnaVirVax 2012 .02 2nd round-financing : 3.7 M€, led by the Pradeyrol Développement family office along with the private equity fund Fa Dièse, the FRCI, and the historical investors managed by CapDecisif Management RFINB [3 years]
InnaVirVax 2010 .01 Research : selection of VAC3S its first vaccine candidate for development and initiation of non clinical development (toxicology studies started in January 2011, ended June) R&D [1 year]
InnaVirVax 2009 .06 1st round-financing : 1.1 M€, by Cap Décisif Management and Genopole 1er Jour RFINA [1 year]
InnaVirVax 2008 .07 Seed financing : 0.45 M€, as a grant by French Ministry of Research and Higher Education (followed by a grant of 1.15 M€ by ANR) SFIN [0 year]
InnaVirVax 2008 .03 Company founded by undisclosed entrepreneurs, based on research by Prof. Patrice Debré and Dr Vincent Vieillard (INSERM U945, AP-HP Pitié-Salpétrière, University Pierre & Marie Curie) ORGF [0 year]
Innovative Health Diagnostics 2011 .07 Clinical trial (phase III) for its blod test IHD-Amy in Alzheimer's disease (83% sensitivity, 82% specificity) CLIN [2 years]
Innovative Health Diagnostics 2010 .03 Seed financing : undisclosed M€, by Sodiv Alsace SFIN [1 year]
Innovative Health Diagnostics 2009 .02 Company founded by Xavier Regnaut, Jean de Barry (researcher Institut des Neurosciences Cellulaires et Intégratives), François Sellal (neurologist) ORGF [0 year]
IntegraGen 2012 .07 Round-financing : 2.0 M€ (reserved private new shares) with fund A Plus Finance RFIN [12 years]
IntegraGen 2012 .04 Launch of ARISk test in USA, a genetic tool to evaluate risk of autism MKTG [11 years]
IntegraGen 2012 .03 Research : launch of a study on 600 autist children to confirm the predictive value of genetic markers in identification of disease, at Cleveland Clinic (Ohio, USA) R&D [11 years]
IntegraGen 2011 .04 Licensing-in of technology with Johns Hopkins University and Massachusetts General Hospital regarding autism diagnostic test ARISk LICIN [10 years]
IntegraGen 2010 .10 Set-up of US subsidiary in Cambridge (Massachussetts) ORGC [10 years]
IntegraGen 2010 .06 Listing on Alternext Paris : 6.7 M€ PBO [9 years]
IntegraGen 2010 .04 Research : positive results on combined analysis of several options in a genetic score to identify individuals with high risks of developing autisme R&D [9 years]
IntegraGen 2010 .02 Licensing-out to Transgenomic to develop and distribute its genetic test of autisme in USA LICOUT [9 years]
IntegraGen 2010 .01 Licensing-in of technology to set-up a service lab in genetic analysis and a demo lab in Europe, from Fluidigm (USA) LICIN [9 years]
IntegraGen 2009 .06 Partnering research agreement with Servier for genotyping applications in Servier's Genese clinical trial R&D [8 years]
IntegraGen 2007 .09 Nomination : Bernard Courtieu as CEO, replacing Jan Mous ORGN [7 years]
IntegraGen 2006 .12 Set-up of US subsidiary (operations) in New York State ORGC [6 years]
IntegraGen 2006 .11 3rd round-financing : 2.0 M€, by Royal DSM, within a research agreement to develop molecular diagnostics RFINC [6 years]
IntegraGen 2005 .11 2nd round-financing : 8.0 M€, by AGF P.E., Société Générale A.M., and previous shareholders RFINB [5 years]
IntegraGen 2004 .01 Research : discovery of a human gene linked to autism R&D [3 years]
IntegraGen 2003 .07 Nomination : Jan Mous as CEO [born 1950, Ph.D., ex-Lion Bioscience AG, as CSO, Roche], replacing Jean-Luc Gerbier ORGN [3 years]
IntegraGen 2001 .06 1st round-financing : 6.3 M€, by CDC Innovation, GenAvent, Bioam, Bay Tech RFINA [0 year]
IntegraGen 2000 .03 Company founded by Philippe Gesnouin (CIO), Jörg Hager, Anne Philippi, Nathalie Vionnet, Jean-Luc Gerbier [CEO, ex-BMS, Biostar], Peter Brooks, as a spin-off from CNG (Centre National du Génotypage) ORGF [0 year]
Ipsogen 2011 .07 Acquisition by Qiagen (preliminary approval to acquire 62.5% stake) ACQ- [11 years]
Ipsogen 2011 .04 Partnering distribution agreement with Sysmex for the Japanese commercialization of certain blood cancer products MKTG [11 years]
Ipsogen 2010 .06 Financing : 1.9 M€ reserved capital increase RFIN [10 years]
Ipsogen 2010 .01 Licensing-in (option) on rights of TET2 abnormalities to improve the diagnosis of Blood-based Disorders, owned by a consortium of 7 public institutions led by IGR&D (IGR) LICIN [10 years]
Ipsogen 2009 .12 Partnering research agreement with Institut Curie, on Genomic Grade, a molecular diagnostic tool for breast cancer R&D [10 years]
Ipsogen 2009 .06 Financing : 2.5 M€ reserved capital increase RFIN [9 years]
Ipsogen 2008 .11 Launch of MapQuant Dx, a new test to determine tumor HER2 status and guide Herceptin prescription in breast cancer (Europe) MKTG [9 years]
Ipsogen 2008 .08 Licensing-out to Quest Diagnostics for the use of the JAK2 V617F mutation into Quest kits in USA researche centers (non-exclusive, followed by Arup, alos for uSA, in May 2009) LICOUT [8 years]
Ipsogen 2008 .06 Listing on Alternext : 11.8 M€, i.e. 35% of shares (oversubscribed) PBO [8 years]
Ipsogen 2007 .11 3rd round-financing : 2.0 M€, by Connecticut Innovations, and previous shareholders RFINC [8 years]
Ipsogen 2005 .03 Set-up of US subsidiary (operations) in Connecticut State ORGC [5 years]
Ipsogen 2005 .02 2nd round-financing : 3.5 M€, by previous shareholders RFINB [5 years]
Ipsogen 2001 .07 1st round-financing : 4.5 M€, led by Société Générale A.M., with Matignon Technologies, Innovéris RFINA [1 year]
Ipsogen 1999 .09 Company founded by Vincent Fert (CEO), Stéphane Debono, Fabienne Hermitte ORGF [0 year]
I-Stem 2011 .11 Creation of Institut des biothérapies (Institute of Biotherapies) to group previously-distinct Généthon, I-Stem, Institut de Myologie, with 700 headcounts LEGAL [6 years]
I-Stem 2009 .06 Partnering research agreement of 7.5 M€ within 2 years with Roche (Swiss), to initiate their teams to I-Stem proprietary technology R&D [4 years]
I-Stem 2007 .01 Set-up of mixed Inserm-UEVE (Université d'Évry-Val d'Essonne) R&D unit ORGC [2 years]
I-Stem 2004 .12 Company founded (without legal entity) by INSERM and AFM (French Muscular Dystrophy Association), as Institute for Stem cell Therapy and Exploration of Monogenic diseases (I-Stem) ORGF [0 year]
Karcinolyslégende 2007 .06 Round-financing : 8 M€ (planned) RFIN [1 year]
Karcinolys 2005 .12 Company founded by Jean-Luc Béjot [ex-Opi], Jean-Baptiste de Cabanes, Jacques de Massignac ORGF [0 year]
Keosys 2012 .02 Partnering strategic agreement with eImage (USA) thru eClinical Technologies offering cost-effective, efficient, centralized, real-time solutions to increase clinical trial sponsors medical imaging ROI MKTG [11 years]
Keosys 2011 .07 Partnering sales agreement with SNM Clinical Trials Network for Imagys (Keosys Web Imaging Platform), in their Phantom Imaging Program MKTG [10 years]
Keosys 2010 .10 Registration : FDA clearance for Keosys Medical Imaging visualization solutions, allowing clinical diagnostic use MKTG [9 years]
Keosys 2008 .12 Launch of new 3D Fusion PACS Viewer system, allowing to distribute volumic exams to any desktop in the hospital and to review them with Keosys 3D Fusion viewer MKTG [7 years]
Keosys 2008 .09 Round-financing : 1.5 M€, by Vizille Capital Innovation (CIC group), Pays de Loire Développement and Lumiplan RFIN [7 years]
Keosys 2006 .00 Seed financing : undisclosed M€, by Sodera (10% capital share) SFIN [4 years]
Keosys 2004 .00 Seed financing : undisclosed M€, by Région Pays de Loire (partly in place of historic shareholder Lumiplan) SFIN [2 years]
Keosys 2002 .00 Launch of Positoscope, a new display tool of digital imaging for Nuclear medicine, aimed to increase distant cooperation between doctors MKTG [0 year]
Keosys 2001 .01 Company founded by Jérôme Fortineau, with 3 engineers, as a SSII and a subsidiary of Lumiplan with IT activities ORGF [0 year]
Mablifelégende 2011 .07 Launch of MAB-Solut new departement, specialised in full spectrum solutions for companies and research labs for antibodies MKTG [11 years]
MABlife 2011 .07 Company rename as MABlife (from MAT Biopharma) with no change in capital structure, and with the same management ORGL [11 years]
MABlife 2009 .01 Nomination : François Vallet, as CEO ORGN [8 years]
MABlife 2008 .09 Clinical trial (phase II) for Ferritarq (completed) CLIN [8 years]
MABlife 2006 .09 Registration : orphan Drug designation by EMEA for Ferritarq MKTG [6 years]
MABlife 2006 .02 Partnering research agreement with Pierre Fabre, on anticancer MABs R&D [6 years]
MABlife 2005 .01 Partnering research agreement with Servier, on anticancer MABs R&D [4 years]
MABlife 2002 .11 Round-financing : 1.25 M€, by undisclosed investors RFIN [2 years]
MABlife 2000 .02 Company founded by Dr Jean Kadouche [born 1945, initial CEO], Raphaël Lévy [M.D., Laennec], Bernard Montanari (initially named Monoclonal Antibodies Therapeutics) ORGF [0 year]
Magnisense 2011 .08 Round-financing : 1 M€, by existing shareholders, to support MIAtek technology platform development RFIN [8 years]
Magnisense 2011 .02 Legal move with Magnisense France as a dissolved company, replaced by Magnisense SE for R&D, and headquarters in Luxemburg ORGF [7 years]
Magnisense 2008 .10 Clinical trial positive, to view and characterize tissue lining the common bile duct at a microscopic level in real time with Cellvizio device, the world's smallest microscope CLIN [5 years]
Magnisense 2008 .04 Launch of MIAplex, a multiparametric magnetic technology MKTG [4 years]
Magnisense 2008 .03 Company expansion with new laboratories facility in Dardilly (near Lyon) ORGC [4 years]
Magnisense 2007 .04 Patent : filed for the invention of a new multiparametric magnetic immunoassay LEGAL [3 years]
Magnisense 2007 .02 Partnering development agreement with Indicia Biotechnology for joint testing platform of magnetic marker-based in vitro diagnostics R&D [3 years]
Magnisense 2006 .12 Nomination : Luc Lenglet, as CEO ORGN [3 years]
Magnisense 2006 .06 2nd round-financing : undisclosed M€, by Baring Vostok Capital Partners and private investors RFINB [3 years]
Magnisense 2006 .03 Patent : filed to protect special features of adapted lateral flow membrane cartridges LEGAL [2 years]
Magnisense 2003 .07 Patent : filed to protect a special embodiment of the technology LEGAL [0 year]
Magnisense 2003 .06 1st round-financing : undisclosed M€, by Baring Vostok Capital Partners and private investors RFINA [0 year]
Magnisense 2003 .05 Company founded by Baring Vostok Capital Partners and private investors, from technical development carried out jointly with the Russian Academy of Sciences in Moscow and Bertin technologies in France for engineering ORGF [0 year]
Mapreg 2008 .03 Round-financing : in preparation, with nomination of next CEO RFIN [7 years]
Mapreg 2008 .02 Registration : orphan Drug designation by EMEA for MAP4343 (trauma of spinal cord) MKTG [7 years]
Mapreg 2000 .10 Company founded by Etienne Emile Baulieu and his team at Kremlin-Bicêtre hospital (Paul Robel, Arlette Fellous, Pascal Azadian), within Inserm premises and support ORGF [0 year]
Mauna Kea Technologies 2011 .08 Registration : positive US FDA clearance for Cellvizio 100 Series endomicroscopy system for the GI and pulmonary tracts MKTG [11 years]
Mauna Kea Technologies 2011 .05 Launch of Cellvizio 100 Series at Digestive Disease Week in Chicago (USA) MKTG [11 years]
Mauna Kea Technologies 2009 .03 Partnering sales agreements with VisualSonics to sell Mauna Kea Technologies' Cellvizio LAB on a Worldwide Basis to Animal Imaging Market MKTG [8 years]
Mauna Kea Technologies 2008 .12 Partnering sales agreements on Cellvizio with Diagmed Healthcare Limited (UK), EndoTécnica (Spain and Greece), RMS Endoscopy (Belgium) MKTG [8 years]
Mauna Kea Technologies 2008 .01 3rd round-financing : 20.5 M€, by U.S.-based Psilos Group, joined by Seventure and by previous shareholder CreAdev RFINC [7 years]
Mauna Kea Technologies 2007 .03 Partnering sales agreement on Cellvizio with Leica Microsystems to benefit researchers using Leica FCM1000 with Cellvizio technology MKTG [6 years]
Mauna Kea Technologies 2006 .11 Partnering sales co-promotion agreement with Invitrogen for In Vivo Imaging Solutions in USA MKTG [6 years]
Mauna Kea Technologies 2006 .05 Launch of Cellvizio-GI at Digestive Disease Week 2006 in Los Angeles (USA) MKTG [6 years]
Mauna Kea Technologies 2000 .05 Company founded by Sacha Loiseau and Benjamin Abrat, under the name Mauna Kea which means «white mountain» in Hawai ORGF [0 year]
Medesis Pharma 2011 .06 Clinical trial (phase IIa) for NP03 in bipolar disorders (beginning) CLIN [8 years]
Medesis Pharma 2011 .01 Clinical trial (phase I) for disease modifying treatment for Huntington’s disease NP03 (completed, published in August 2012) CLIN [7 years]
Medesis Pharma 2010 .05 Clinical trial (phase I) for anti-diabetic NP01 (completed) CLIN [7 years]
Medesis Pharma 2009 .12 Registration : orphan Drug positive opinion by EMEA for treatment of Huntington's disease (NP03) MKTG [6 years]
Medesis Pharma 2008 .04 Financing (no interest loan) : 0.9 M€, by OSEO and Languedoc-Roussillon region, to support its ongoing program for NP01 in diabetes DEBT [5 years]
Medesis Pharma 2008 .01 Company move from Paris to Baillargues (10km from Montpellier) ORGL [4 years]
Medesis Pharma 2006 .01 Clinical trial planned, after first preclinical trial results on NP01 on metabolic syndrome CLIN [2 years]
Medesis Pharma 2003 .04 Company founded by Jean-Claude Maurel, headquartered in Baillargues (today : labs location) ORGF [0 year]
Mellitech 2011 .07 Round-financing : 0.4 M€, by existing shareholders and several business angels RFIN [5 years]
Mellitech 2009 .10 Proof-of-concept for lead ZnT8 agonist compound : insulin secretion enhanced in normal WT mice and unchanged in mice knocked-out for the slc30a8 gene R&D [4 years]
Mellitech 2009 .06 Round-financing : 0.3 M€, by business angels RFIN [3 years]
Mellitech 2009 .03 Nomination : Richard Platford, as CEO, replacing Philippe Barth ORGN [3 years]
Mellitech 2007 .12 Seed financing : 0.5 M€, by business angels SFIN [2 years]
Mellitech 2006 .11 Nomination : Philippe Barth, as CEO ORGN [1 year]
Mellitech 2005 .10 Company founded by Pierre-Marie Girod-Roux, Michel Sève, Yann de Boysson, as a spin-off from UJF (Université Joseph Fournier) and CEA ORGF [0 year]
Metabolys 2009 .01 Financing : expression of interest, first call IMI RFIN [0 year]
Metabolys 2008 .11 Company founded by Gabriel Baverel, as a spin-off from Claude-Bernard University, in Lyon ORGF [0 year]
MilleGen 2010 .08 Research : publication in Methods Mol Biology of random mutagenesis method (human error-prone DNA polymerases) R&D [10 years]
MilleGen 2010 .03 Patent : granted on molecular evolution technology (MutaGen) by US office LEGAL [10 years]
MilleGen 2008 .05 Partnering research agreement with Accuro Biologics on reciprocal expertise R&D [8 years]
MilleGen 2007 .03 Partnering research agreement with LFB to develop new generation of therapeutic monoclonal antibodies R&D [7 years]
MilleGen 2005 .09 Partnering research agreement with Pierre Fabre, bio-informatics R&D [5 years]
MilleGen 2001 .12 Launch of MutalGen platform, a mutagenesis platform MKTG [2 years]
MilleGen 1999 .10 Company founded by 2 researchers, Hakim Kharrat and Khalil Bouayadi ORGF [0 year]
Murigenetics 2011 .02 Nomination : Marine Berro as CEO (previously COO), replacing Morgane Le Boulay ORGN [5 years]
Murigenetics 2008 .02 Registration : orphan Drug designation by EMEA for Ascorbic Acid in Charcot disease MKTG [2 years]
Murigenetics 2005 .08 Company founded by Prof. Michel Fontès, Prof. Olivier Blin, Eric Halioua, Gwenhaël Le Boulay ORGF [0 year]
NanoBiotixlégende 2012 .11 Clinical trial (phase I) for NBTXR3 in the treatment of advanced Soft Tissue Sarcoma of the extremity (beginning) at IGR CLIN [9 years]
NanoBiotix 2010 .06 3rd round-financing : 8.3 M€, led by CIC Vizille Capital Innovation with Masseran Gestion, and existing shareholders, Matignon Technologies, OTC Asset Management, Cap Decisif Management, and Amorçage Rhône-Alpes RFINC [7 years]
NanoBiotix 2009 .01 Partnering research agreement with SonoDrugs consortium (Philips, Lipoid AG, and 13 universities within a 16 M€ budget) to develop new nanoparticulate drug carriers R&D [5 years]
NanoBiotix 2008 .09 Patent : granted on nanoXray anticancer platform (Europe) LEGAL [5 years]
NanoBiotix 2006 .11 2nd round-financing : 7.0 M€, by Matignon Technologies, OTC Asset Management, and previous shareholders RFINB [3 years]
NanoBiotix 2005 .03 Company move from Labège (near Toulouse) to Paris ORGL [2 years]
NanoBiotix 2004 .00 1st round-financing : 1.0 M€, by Buffalo University (USA) and founders RFINA [0 year]
NanoBiotix 2003 .03 Company founded by Laurent Levy (born 1971), Kader Boussaha , and 4 others ORGF [0 year]
Neorphys 2009 .08 1st round-financing : 1.2 M€, by Soridec, CEA Valorisation, Fa Diese 2, Seillans and a number of independent business angels RFINA [3 years]
Neorphys 2007 .03 Seed financing : 0.3 M€, by Soridec and Inserm-Transfert Initiative (extended to 1.05 M€ in total, mid 2008, with CEA Valorisation as additional investor) SFIN [1 year]
Neorphys 2006 .07 Financing (no interest loan) : 0.25 M€, by OSEO Innovation and Crealia DEBT [0 year]
Neorphys 2005 .09 Company founded by Roger Lahana and Karine Larbouret ORGF [0 year]
Neovacs 2013 .02 Financing (capital increase): 6.25 M€, with preemptive subscription rights for existing shareholders PBO [19 years]
Neovacs 2012 .11 Clinical trial (phase II) for TNFa-kinoid, a therapeutic vaccine in crohn's disease (end) CLIN [19 years]
Neovacs 2011 .11 Clinical trial (phase I/II) for TNFa-kinoid, a therapeutic vaccine in lupus (end) CLIN [18 years]
Neovacs 2011 .06 Financing (no interest loan) : 1.5 M€, by OSEO Innovation to support Tracker (follow-up of 2008 deal) DEBT [18 years]
Neovacs 2011 .04 Financing (capital increase): 2.25 M€ by Debiopharm, Truffle Venture and OTC Asset Management [followed in June by 0.4 M€, dedicated to foreign shareholders) PBO [18 years]
Neovacs 2010 .12 Clinical trial (phase II) for TNFa-kinoid, a therapeutic vaccine in rheumatoid arthritis (end, with promising results) CLIN [17 years]
Neovacs 2010 .04 Listing on Alternext : 10 M€ (IPO) PBO [17 years]
Neovacs 2009 .12 Clinical trial (phase II) for TNFa-kinoid, a therapeutic vaccine in rheumatoid arthritis patients failing TNFa monoclonal antibody therapy (beginning) CLIN [16 years]
Neovacs 2008 .11 Clinical trial (phase I-II) for TNFa-kinoid, a therapeutic vaccine for the treatment of TNFa dependent auto-immune diseases in South-Africa (beginning) CLIN [15 years]
Neovacs 2008 .10 Financing (no interest loan) : 5.4 M€ (and 2.5 M€ grant), by OSEO Innovation to support Tracker, a theranostics project concerning rheumatoid arthritis from Neovacs (leader) and Biomedical Diagnostics DEBT [15 years]
Neovacs 2007 .07 Round-financing : 13.0 M€, by Novartis and previous shareholders RFIN [14 years]
Neovacs 2006 .06 Licensing-out to Debiopharm with capital sharing LICOUT [13 years]
Neovacs 2006 .06 Nomination : Guy Fanneau de la Horie, as CEO ORGN [13 years]
Neovacs 2004 .10 Round-financing : 1.5 M€, by Truffle Ventures and 1.2 M€, by Anvar RFIN [11 years]
Neovacs 2003 .07 Nomination : Alain Huriez, as CEO (still, as Director, Truffle Venture) ORGN [10 years]
Neovacs 2003 .06 Round-financing : 3.5 M€, by Truffle Ventures and Europe Innovation (reaching 51% of capital) RFIN [10 years]
Neovacs 1999 .00 Licensing-out of HIV therapeutic vaccine to Aventis Pasteur LICOUT [5 years]
Neovacs 1998 .00 Nomination : Jean-François Bensahel, as CEO ORGN [4 years]
Neovacs 1993 .04 Company founded by Daniel Zagury (immunologist), as a spin-off from Pierre et Marie Curie Paris University ORGF [0 year]
Netris-Pharma 2009 .09 Nomination : Agnès Bernet, as CEO, replacing Rodolphe Pasquier-Desvignes ORGN [1 year]
Netris-Pharma 2008 .06 Company founded by Patrick Mehlen [Lyon University, CNRS, as head of scientific board], Agnès Bernet [Lyon University], and Rodolphe Pasquier-Desvignes, as CEO ORGF [0 year]
Neuronax 2012 .10 Financing (no interest loan) : 0.6 M€, by Oseo, for its NX210 Project DEBT [9 years]
Neuronax 2006 .05 Licensing-out to Cells4Health (Holland) of first lead product NX peptide for clinical development LICOUT [3 years]
Neuronax 2005 .06 Patent : granted in USA on peptide LEGAL [2 years]
Neuronax 2003 .03 Company founded by Stéphane Gobron, Dr Fabrice Cailloux, Pierre-Yves Simonin [Pharm.D.], as a spin-off from Inserm ORGF [0 year]
NewVectys 2010 .11 Company founded by Jacques Mallet [Ph.D., chairman scientific committee], Chamsy Sarkis, and Antoine Duboscq ORGF [0 year]
NicOx 2012 .10 Launch of AdenoPlus in USA (new device for differential diagnosis of acute conjunctivitis) MKTG [16 years]
NicOx 2012 .04 Acquisition of 11.8 % stake in UK Altacor (to build an international ophthalmology business) for 2.0 M€, with option to acquire the entire company (declined in June) ACQ+ [16 years]
NicOx 2012 .03 Clinical trial (phase IIb) for BOL-303259-X (end, positive), a novel nitric oxide-donating prostaglandin F2-alpha analog, in patients with open-angle glaucoma (with Bausch & Lomb) CLIN [16 years]
NicOx 2011 .12 Management restructuring : 33% heads employee reduction (after 50 heads dropped earlier in 2010) ORGR [15 years]
NicOx 2011 .09 Development : preclinical data for NCX 6560, a nitric oxide (NO)-donating atorvastatin R&D [15 years]
NicOx 2011 .03 Partnering distribution agreement with Ferrer (Spain) on co-marketing rights of naproxcinod in Spain and Germany, and on exclusive marketing rights in Greece and Portugal MKTG [15 years]
NicOx 2010 .08 Closure of US subsidiary (headquarters) in New Jersey ORGC [14 years]
NicOx 2010 .05 Registration : FDA advisory panel rejects naproxcinod (stock market off 45%, after announcement) MKTG [14 years]
NicOx 2009 .12 Public offering : 100 M€, with capital increase (closed) to FSI (€ 20 Millions), public funds (€ 10 Millions) and existing shareholders (€ 70 Millions) PBO [13 years]
NicOx 2009 .09 Registration : FDA submission of naproxcinod (then, EMEA, in December) MKTG [13 years]
NicOx 2009 .08 Acquisition (re-acquisition) of rights to PF-03187207 for glaucoma from Pfizer for 2 undisclosed milestones ACQ+ [13 years]
NicOx 2009 .04 Acquisition of Nitromed's unlicensed patent estate covering nitric oxide-donating compounds for up to 6.0 M€ ACQ+ [13 years]
NicOx 2008 .09 Partnering secondary production agreement with Capsugel for the manufacture of Naproxcinod INDUS [12 years]
NicOx 2008 .05 Partnering primary production agreement with Archimica for the manufacture of Naproxcinod INDUS [12 years]
NicOx 2007 .10 Set-up of US subsidiary (headquarters) in New Jersey ORGC [11 years]
NicOx 2007 .07 Round-financing : 5.0 M€, by M.S.D., as milestone payment for licensing-in drug for hypertension RFIN [11 years]
NicOx 2007 .02 Public offering : 130 M€, with capital increase PBO [11 years]
NicOx 2006 .05 Clinical trial (phase III) for HCT3012 osteoarthritis drug (end of patient recrutment) CLIN [10 years]
NicOx 2006 .04 3rd round-financing : 45.5 M€, for private international investors, with share increase and subsequent listing on Euronext RFINC [10 years]
NicOx 2004 .10 2nd round-financing : 26.0 M€, for private international investors, with share increase and subsequent listing on Euronext RFINB [8 years]
NicOx 2003 .02 Financing : stock drop-down from 210 M€ to 36 M€ (max.: 450 M€ in June 2002), after disappointing results of clinical study INFO [7 years]
NicOx 2004 .08 Partnering research agreement with Pfizer R&D [8 years]
NicOx 2001 .09 Set-up of R&D center in northern Italy ORGC [5 years]
NicOx 2001 .05 Public offering : 59.0 M€ PBO [5 years]
NicOx 1999 .11 Listing on Paris Nouveau Marché : 27.4 M€ PBO [3 years]
NicOx 1998 .06 Company move from Paris to Sophia Antipolis (near Nice) ORGL [2 years]
NicOx 1998 .03 Partnering research agreement with Bayer (first of long series) R&D [2 years]
NicOx 1997 .12 1st round-financing : 6.4 M€, led by Paribas P.I., Health Capital AB, with previous investors RFINA [1 year]
NicOx 1996 .10 Clinical trial (phase I) for anti-thrombotic (beginning) CLIN [0 year]
NicOx 1996 .02 Company founded by 3 pharmaceutical executives, Michele Garufi (CEO), Piero del Soldato, Elizabeth Robinson, from a primary legal entity in Eire in 1994, with financial support of Apax Partners, Sofinnova, European Medical Ventures ORGF [0 year]
Nokad 2009 .10 2nd round-financing : 1.6 M€, led by SHAM RFINB [5 years]
Nokad 2008 .12 Financing : grant of 0.9 M€, by ANR (Agence Nationale pour la Recherche) to support therapeutic vaccine projects in partnership with INSERM U790 Unit DEBT [4 years]
Nokad 2007 .04 Research : first fonctional KO mouse obtained, leading to a new function of erythropoietin receptor R&D [3 years]
Nokad 2006 .04 Set-up of US branch in Cambridge (MA) ORGC [2 years]
Nokad 2005 .07 Seed financing : undisclosed M€, by Cap Décisif and Genopole 1er Jour SFIN [1 year]
Nokad 2004 .01 Company founded by François Erard, Aymeric Dugray [left company in 2008], Abdelkader Yacchou, based on a project incubated by Amine Abina (before 2003) ORGF [0 year]
Nosopharm 2009 .02 Company founded by Philippe Villain-Guillot and Maxime Gualtieri ORGF [0 year]
NovAliX 2012 .01 Partnering R&D agreement with Teijin Pharma for a multi-target integrated drug discovery collaboration (through Graffinity) R&D [9 years]
NovAliX 2011 .08 Partnering R&D agreement with Galapagos in osteoarthritis (through Graffinity) R&D [8 years]
NovAliX 2011 .03 Partnering R&D agreement with Shionogi (through Graffinity) R&D [8 years]
NovAliX 2010 .11 Acquisition of Graffinity (Germany), with proprietary fragment-based SPR drug discovery technology ACQ+ [7 years]
NovAliX 2009 .01 Partnering R&D agreement with Sosho, an Osaka university spin-off, for protein structure determination of intractable targets R&D [6 years]
NovAliX 2008 .10 Acquisition of Novalix (by merger and integration), a contract research biotech company (60 employees) specialised in protein production and cristallography analysis [company renamed as NovaliX and AliX name discontinued in 2011] ACQ+ [5 years]
NovAliX 2008 .09 Nomination : Denis Zeyer, new CEO, replacing Jean-Paul Renaud, back to academic activities ORGN [5 years]
NovAliX 2002 .11 Company founded as AliX by Jean-Paul Renaud, Jean Cavarelli, Dino Moras, Olivier Poch, Marc Ruff, Jean-Claude Thierry, Jean-Marie Wurtz, and Marat Yusupov, as a spin-off from the Department of Structural Biology and Genomics (DBGS) of the Institute of Genetics and Molecular and Cellular Biology (IGBMC) ORGF [0 year]
NovoCIB 2006 .11 Nomination : Nicolas Godard as CEO, from a consultancy position in Genopole Évry ORGN [1 year]
NovoCIB 2006 .05 Company move from Grenoble to the former site of Merck-Lipha Santé, in Lyon city center ORGL [1 year]
NovoCIB 2005 .05 Company founded by Larissa Balakireva ORGF [0 year]
Novotec 1997 .11 Company founded by Sylviane Guerret, as a spin-off from Institut Pasteur, Lyon ORGF [0 year]
ObeTherapylégende 2005 .06 Partnering research agreement with Zambon (later acquired by Rottapharm), on low-molecular weight R&D [5 years]
Obe Therapy 2002 .11 Seed financing : 0.3 M€, by iXCore SFIN [2 years]
Obe Therapy 2000 .01 Company founded by Itzik Harosh, with public funds (Genopole 1er Jour, Anvar), amounting to 0.4 M€ ORGF [0 year]
Oligovax 2001 .08 Seed financing : 0.8 M€, by Global Millenium Fund SFIN [1 year]
Oligovax 2000 .08 Company founded by Paul van der Schueren, from AP-HP licensed patents ORGF [0 year]
Oncodesign 2012 .09 Partnering R&D agreement with Sanofi for the application of Oncodesign’s Nanocyclix technology to kinase targets R&D [17 years]
Oncodesign 2012 .01 Partnering R&D agreement with Ipsen on LRRK2 Parkinson's disease target R&D [17 years]
Oncodesign 2011 .10 Partnering development and distribution agreement with Taconic (USA) for solutions to advance oncology research MKTG [16 years]
Oncodesign 2010 .06 Licensing-in of macrocyclic chemistry technology from Janssen LICIN [15 years]
Oncodesign 2009 .08 Financing (no interest loan) : 10.0 M€, by OSEO Innovation, for oncology biomarker program IMAkinib (with Guerbet and Ariana Pharmaceuticals) DEBT [14 years]
Oncodesign 2008 .06 Round-financing : 3.0 M€, by Banque de Vizille, Avenir Entreprise Gestion, in order to invest in USA and neurology RFIN [13 years]
Oncodesign 2008 .03 Launch of Pharm'Image platform, a medical imagery pole in Dijon, with local partners (completion planned for 2010) MKTG [13 years]
Oncodesign 2007 .07 Set-up of offices in Montréal, Canada ORGC [12 years]
Oncodesign 1998 .07 Seed financing : 0.75 M€, by Ideb, Banque Populaire Création SFIN [3 years]
Oncodesign 1995 .01 Company founded by Philippe Genne and Eric Solary (today Inserm), both scientists (Lab. Onco-hematology, Dijon University) ORGF [0 year]
OriBase Pharma 2010 .09 Company name change from Nova Decision to OriBase Pharma, after merger with local neighbor Azasynth (and move to larger premices in Montpellier) INFO [3 years]
OriBase Pharma 2008 .10 Partnering research collaboration (Nova Decision) with UCB using HitFast and SelectiveLead proprietary tools R&D [1 year]
OriBase Pharma 2008 .05 Partnering research collaboration (Nova Decision) with Ingenious Targeting laboratories (ITL) for a lead optimization program at ITL R&D [0 year]
OriBase Pharma 2007 .09 Company founded by Aziz Yasri as Nova Decision, based on SARA v 1.0, a powerful QSAR/QSPR datamining platform for parallel and automatic descriptor selection and model building ORGF [0 year]
OriBase Pharma 2007 .08 Company founded by Louis Delon as AzaSynth ORGF [0 year]
Oroxcell 2007 .06 Launch of new technology cosmetic testing based on human skin, in cooperation with Episkin and Skinethic MKTG [2 years]
Oroxcell 2007 .00 Partnering contract agreement with Nosan (Japan) as their total agency in the medical product absorption R&D [2 years]
Oroxcell 2004 .07 Company founded by Jean Pachot ORGF [0 year]
Oxincell 2006 .08 Company founded by Dr Christelle Peyreigne and Dr Jean-Pierre Molès ORGF [0 year]
Palumedlégende 2009 .06 Financing (no interest loan) : 9.0 M€, by OSEO Innovation, for the NOSOBIO program for prevention, diagnostics and treatment of hospital-acquired infections (with Serial Genetics, Genewave, Da Volterra, Institut Pasteur and Assistance Publique-Hôpitaux de Paris) DEBT [8 years]
Palumed 2008 .05 Patent : pending on 3rd generation Trioxaquines with Sanofi-Aventis LEGAL [7 years]
Palumed 2006 .02 Nomination : Bernard Meunier as CEO, replacing Claudine Meunier-Chesny (moving to Alliances Dir.) ORGN [5 years]
Palumed 2002 .07 1st round-financing : undisclosed M€, by IRDI, SOCRI, FCJE (CDC), GSO Capital, followed by Viveris (2005) RFINA [1 year]
Palumed 2000 .12 Company founded by Bernard Meunier and Claudine Meunier-Chesny ORGF [0 year]
PharmaLeads 2011 .11 Clinical trial (phase II) for PL 37, own analgesic drug (beginning, afetr positive outcome of phase I) CLIN [10 years]
PharmaLeads 2008 .11 Licensing-out of analgesic PL37 to Debiopharm (Switzerland), beginning phase I, with € undisclosed Millions upfront payment LICOUT [7 years]
PharmaLeads 2008 .10 Clinical trial (phase I) for PL 37, own analgesic drug (beginning) CLIN [7 years]
PharmaLeads 2006 .04 Launch of new Fluofast high fluorescence library of peptide enzymes MKTG [5 years]
PharmaLeads 2005 .01 Management reshuffling : managers replacing scientific founders in operations ORG [4 years]
PharmaLeads 2000 .12 Company founded by a group of Inserm researchers led by Bernard Roques (Pharm.D., Ph.D. Physico-chemistry) and Marie-Claude Fournié-Zaluski (CEO, Ph.D. Chemistry) ORGF [0 year]
Pharnext 2012 .02 3rd round-financing : € 8.0 Million, as a private placement RFINC [4 years]
Pharnext 2011 .11 Clinical trial (phase II) for PXT3003 (the company’s first Pleodrug) in Charcot-Marie-Tooth disease (completed) CLIN [4 years]
Pharnext 2011 .09 2nd round-financing : € 2.5 Million, by Parinvest (Jean-Charles Naouri), La Financière Gaspard, Truffle Capital RFINB [4 years]
Pharnext 2010 .06 1st round-financing : € 4.8 Million led by Truffle Capital, with Aurinvest, Financière Boscary and private investors (Charles Beigbeder, Claude Darmon, Olivier Fulconis) RFINA [3 years]
Pharnext 2009 .06 Partnering R&D marketing agreement with Ipsen regarding innovative drug candidates intended for the treatment of Charcot Marie-Tooth disease, issued from the pleotherapy technology, against undisclosed amount of convertible bonds, milestones and upfront (94 M€ worth maximum) R&D [2 years]
Pharnext 2007 .11 Seed financing : 2.5 M€, by Truffle Capital SFIN [0 year]
Pharnext 2007 .07 Company founded by Daniel Cohen (CEO), researchers of his team and Philippe Pouletty (Truffle Capital) ORGF [0 year]
PhenoPro 2008 .08 Partnering marketing agreement with Oncodesign, OncOptima, a new service offer for the characterization and validation of Genetically Engineered Mouse Model in cancer targeted therapies MKTG [0 year]
PhenoPro 2007 .09 Company founded by Nicolas Carboni (chairman, plus Managing Director of the Cluster Alsace-Biovalley, up to 2011), Catherine Schaeffer, and others, as a spin-off from MCI (Mouse Clinical Institute) ORGF [0 year]
Pherecydes Pharma 2012 .02 Financing : 1.2 M€ from Defense agency, as a funding for evaluating the use of bacteriophages against infected, antibiotic resistant burns RFIN [5 years]
Pherecydes Pharma 2010 .08 Research : publication in Biosecurity and Bioterrorism on genetically engineered virulent phages to detect and control emergent pathogenic bacteria R&D [3 years]
Pherecydes Pharma 2009 .09 Nomination : Jérôme Gabard, replacing Thierry Raynaud (since beginning) ORGN [2 years]
Pherecydes Pharma 2009 .08 Financing (no interest loan) : 0.5 M€, by OSEO, for development and validation of 3 patented technologies, using its predictive integrative biology process (CADI) DEBT [2 years]
Pherecydes Pharma 2009 .08 1st round-financing : 1.15 M€, by undisclosed investors RFINA [2 years]
Pherecydes Pharma 2008 .10 Company move from Paris to Biocitech in Romainville ORGL [1 year]
Pherecydes Pharma 2006 .12 Company founded by Manuel Géa, as a spin-off from BMSystems ORGF [0 year]
PolyIntell 2008 .11 Company move from Mont-Saint-Aignan (near Rouen) to Val-de-Reuil (Eure) with 700 m2 new laboratories ORGL [4 years]
PolyIntell 2008 .09 Seed financing : 0.8 M€, by 2 venture capitalists SFIN [4 years]
PolyIntell 2004 .07 Company founded by Kaynoush Naraghi, Sami Bayoudh (husband), and Karsten Haupt (Scientific advisor) ORGF [0 year]
Proteogenix 2003 .01 Company founded by Philippe Funfrock with Inserm researchers
(URL, also as www.proteogenix.fr : no link with the homonym US biotech)
ORGF [0 year]
Protexel 2000 .08 Company founded by Bernard Weill, Frédéric Batteux, as a spin-off of AP-HP (Cochin hospital), in Paris Biotech center ORGF [0 year]
PX'Therapeutics 2012 .10 Acquisition by Aguettant (majority stake, but non-operational), co-founders still managing company ACQ- [11 years]
PX'Therapeutics 2012 .03 Clinical trial (phase I) for EuroNeut-41 Prophylactic HIV Vaccine in healthy female volunteers (beginning) CLIN [11 years]
PX'Therapeutics 2011 .00 Licensing-in from Ribovax (Switzerland) of Sebvi technology for the development and manufacturing of fully human monoclonal antibodies LICIN [10 years]
PX'Therapeutics 2010 .12 Production : new additional biomanufacturing unit, dedicated to mammalian cell culture production (opening facility) INDUS [10 years]
PX'Therapeutics 2010 .08 Set-up of new subsidiary Promise Advanced Proteomics, offering unique protein Absolute Quantification services ORGC [9 years]
PX'Therapeutics 2009 .11 Production : new additional biomanufacturing unit, dedicated to the production of therapeutic proteins and monoclonal antibodies in mammalian cells, in Grenoble (10th anniversary) INDUS [9 years]
PX'Therapeutics 2008 .10 Partnering manufacturing agreement with Alizé Pharma on a recombinant L-asparaginase INDUS [7 years]
PX'Therapeutics 2008 .09 Company name change from ProteineXpert to PX'Therapeutics, in order to highlight its focus on integrated biotherapeutics development and to avoid labeling confusions INFO [7 years]
PX'Therapeutics 2008 .07 Partnering co-commercialization agreement with Althea Technologies (San Diego, USA) MKTG [7 years]
PX'Therapeutics 2007 .07 Set-up of PX'Monoclonals subsidiary in Lyon, dedicated to the development of murine and humanized monoclonal antibodies for research and therapeutic purposes ORGC [6 years]
PX'Therapeutics 2004 .09 Set-up of PX'Pharma subsidiary to provide with cGMP clinical manufacturing services ORGC [3 years]
PX'Therapeutics 2003 .11 Round-financing : 1.3 M€, by undisclosed regional investors RFIN [3 years]
PX'Therapeutics 2000 .11 Company founded by Tristan Rousselle and Nicolas Mouz ORGF [0 year]
Quantum Genomicslégende 2012 .10 Clinical trial (phase Ia) with QGC001 for the treatment of hypertension (completed, successful) CLIN [6 years]
Quantum Genomics 2011 .02 Financing (grant) : 1.0 M€, by ANR, to finance the beginning of the clinical development of QGC 001 RFIN [5 years]
Quantum Genomics 2009 .04 Financing (no interest loan) : 0.7 M€, by OSEO Innovation, to finance the regulatory preclinical development of QGC 001 (the first drug to treat hypertension by targeting Aminopeptidase A) DEBT [3 years]
Quantum Genomics 2008 .01 Acquisition of Eurobiobiz (Clermont-Ferrand), specialized in high-value added project management ACQ+ [2 years]
Quantum Genomics 2007 .06 Partnering research agreement with Inserm and CNRS on their hypertension chemical entity, as QGC001 R&D [1 year]
Quantum Genomics 2006 .07 1st round-financing : 3.0 M€, led by undisclosed investors RFINA [0 year]
Quantum Genomics 2006 .06 Company founded by US investors (New Jersey), with European HQ and management in Paris region ORGF [0 year]
Rhenovia Pharmalégende 2012 .04 2nd round-financing : € 3.1 Million, by undisclosed investors to support new biosimulation drug discovery programs for Huntington Disease and Duchenne muscular dystrophies RFINB [4 years]
Rhenovia Pharma 2012 .02 Set-up of Rhenovia Inc, based in the Greater Boston Area with offices in Cambridge, Massachusetts ORGC [4 years]
Rhenovia Pharma 2011 .05 Partnering marketing agreement with Portmann Instruments for Rhenovia's biosimulation services in Switzerland LICOUT [4 years]
Rhenovia Pharma 2011 .04 Partnering R&D agreement with Sodiaal-Candia for studying the nutritional and therapeutic value of milk and its derivatives R&D [3 years]
Rhenovia Pharma 2010 .12 Partnering research collaborative project with AFM (Association Française des Myopathies) for 0.5 M€ over 2 years to support their simulation technology for diseases of the nervous system R&D [3 years]
Rhenovia Pharma 2010 .07 Company headquarters move in new buildings, still in Mulhouse ORGL [3 years]
Rhenovia Pharma 2010 .04 Partnering research collaborative project RHENEPI lead for 2.5 M€ over 3 years in order to develop a platform biosimulation of seizures (other partner Synapcell as CRO) R&D [2 years]
Rhenovia Pharma 2009 .04 Financing (grant) : 1.6 M€ (2.3 MUS$), by state R&D institution NIH (USA) shared by Biomedical Engineering, LAS and Rhenovia, over 4 years RFIN [1 year]
Rhenovia Pharma 2007 .05 Company founded by Serge Bischoff, Pr. Michel Baudry, Jan Kremers, and Michel Faupel ORGF [0 year]
ScarCell Therapeuticslégende 2007 .04 Company founded by Antoine Lafont (M.D., APHP, Directeur de l'Unité Inserm U849), Bruno Gogly (M.D., APHP, Inserm U849), Bernard Coulomb (Ph.D., Inserm U849), as a spin-off of AP-HP (Cochin hospital), in Paris Biotech center ORGF [0 year]
Sisène Biotechnologies 2012 .00 Financing (grant) : 0.1 M€, by Georgia Research Alliance to support international drug development collaboration with GHSU cancer center RFIN [4 years]
Sisène Biotechnologies 2012 .09 Set-up of Sisene Inc, based in Augusta (Georgia, USA) ORGC [5 years]
Sisène Biotechnologies 2008 .05 Management major setback : Jean Plouët's death ORG [1 year]
Sisène Biotechnologies 2008 .03 Financial minority share (8.5%) acquired by Théa Laboratories (ophthalmology) ACQ- [0 year]
Sisène Biotechnologies 2007 .05 Company founded by Prof. Jean Marsac and Jean Plouët (co-discoverer of Vegf) ORGF [0 year]
Skuld-Tech 2012 .11 Partnering research agreement with Biotech ABScience to develop a companion diagnostic test associated with masitinib based on new predictive markers for pancreatic cancer survival R&D [13 years]
Skuld-Tech 2007 .02 Partnering research agreement with Roche Diagnostics on rapid and accurate SAGE gene profiles R&D [7 years]
Skuld-Tech 2006 .03 Partnering research agreement with Genepep R&D [6 years]
Skuld-Tech 1999 .06 Company founded by Didier Ritter, Dr Philippe Piquemal, Philippe Outrebon, as a spin-off from Institut de Génétique Humaine (Montpellier) ORGF [0 year]
Stentys 2012 .11 Financing (capital increase) : 36.0 M€, notably by state FSI (hence 7.8% of K) to finance a clinical study in USA and recruit a sales force in Europe RFIN [6 years]
Stentys 2012 .05 Clinical trial of Apposition III (published, 1 month's follow-up : mortality at 1.2% compared to 3.5% in pooled analysis of conventional stents) CLIN [5 years]
Stentys 2011 .03 Launch of drug-eluting stent in 4 additional EU countries, Scandinavia, Spain, Switzerland and Poland MKTG [4 years]
Stentys 2011 .02 Launch of drug-eluting stent in Germany, with increased reimbursement (and also the Netherlands) MKTG [4 years]
Stentys 2010 .10 Listing on Euronext : 22.7 M€ (IPO) PBO [4 years]
Stentys 2009 .12 Clinical trial of Apposition vs. standard stent (beginning) CLIN [3 years]
Stentys 2009 .09 Clinical trial of Apposition, first self-expanding stent (results) CLIN [3 years]
Stentys 2006 .07 Company founded by Jacques Séguin [M.D. cardiology, Ph.D., ex-founder CoreValve] and Gonzague Issenmann [company also based in Princeton, New Jersey, USA] ORGF [0 year]
Synapcell 2011 .04 Partnering research agreement with MedGenesis Therapeutix Inc. to provide animal proof of concept for lead product of MedGenesis, GDNF, in chronic epilepsy R&D [6 years]
Synapcell 2009 .03 Seed financing : 0.7 M€ by Rhône-Alpes Création, Expansinvest, Grenoble Angels Participation, Viaduc8 SFIN [3 years]
Synapcell 2005 .04 Company founded by Corinne Roucard, Karine Bressand, Yann Roche, Antoine Depaulis (based on a trade name already active in 2002), based on a project stemmed in Université Joseph Fourier (Grenoble) ORGF [0 year]
Synprosis 2008 .04 Seed financing : 0.15 M€ by Nortia, Venice SFIN [4 years]
Synprosis 2003 .06 Company founded by Jean-Pierre Salles, in cooperation with Erwan Loret ORGF [0 year]
TcLand Expressionlégende 2012 .05 Nomination : John Tchelingerian, as Chairman and CEO [ex-Diatos] ORGN [9 years]
Tc Land Expression 2011 .06 Financing (no interest loan) : 1.2 M€, by OSEO and ERDF to support a leading project in personalised medicine focused on rheumatoid arthritis DEBT [8 years]
Tc Land Expression 2011 .03 Partnering research agreement within the Innovative Medicines Initiative (IMI) Be The CURE, the largest European consortium for Rheumatology R&D [8 years]
Tc Land Expression 2010 .07 Partnering research agreement with Inserm Transfert, on the development of companion diagnostic tests for rheumatoid arthritis therapies R&D [7 years]
Tc Land Expression 2010 .05 Financing (no interest loan) : 0.45 M€ from ANR for diagnostic program in rheumatoid arthritis DEBT [7 years]
Tc Land Expression 2009 .10 Clinical trial for validation study on K-RejX diagnostic blood test in identification of kidney transplant recipients at risk of chronic rejection (beginning) CLIN [7 years]
Tc Land Expression 2009 .09 Round financing : 1.0 M€ through Tepa law (plus 2.2 M€ as no interest loan from ANR for Tolestim development), to Tc Land Pharma RFIN [6 years]
Tc Land Expression 2009 .04 Financing (no interest loan) : 1.8 M€ from OSEO for innovation support DEBT [6 years]
Tc Land Expression 2008 .08 Licensing-in of a liver biomarker (worldwide rights) from Idibaps (Spain) LICIN [5 years]
Tc Land Expression 2008 .01 Set-up of CIMNA, an integrated immuno-monitoring service platform, located in Nantes ORGC [5 years]
Tc Land Expression 2007 .12 1st round-financing : 8.2 M€, led by Auriga Partners RFINA [5 years]
Tc Land Expression 2007 .12 Company split into 2 autonomous units : TcLand Expression (previously TcLand) and TcLand Pharma, focused on the development of therapeutic molecules ORG [5 years]
Tc Land Expression 2006 .00 Nomination : Alain Huriez, as Chairman and CEO [ex-Neovacs CEO, 2003-2006] ORGN [3 years]
Tc Land Expression 2006 .06 Licensing-out to Debiopharm with capital sharing LICOUT [3 years]
Tc Land Expression 2005 .06 Seed financing : undisclosed M€, by Inserm-Transfert SFIN [2 years]
Tc Land Expression 2002 .10 Company founded by Marina Guillet, Alain Huriez, as a spin-off of Itert ORGF [0 year]
Theraclion 2012 .03 Nomination : Jean-Yves Burel, new CEO, replacing Ismaël Nujurally ORGN [7 years]
Theraclion 2012 .01 TH-one for EchoTherapy, renamed as EchoPulse MKTG [7 years]
Theraclion 2011 .11 Clinical trial (phase III) for a non-invasive treatment of breast fibroadenomas (2 patients) CLIN [7 years]
Theraclion 2010 .09 Nomination : Ismaël Nujurally, new CEO, replacing François Lacoste (as CSO) ORGN [6 years]
Theraclion 2009 .02 Financing (no interest loan) : 8.5 M€ (of which 3.5 M€ as grant), OSEO Innovation, as part of the TUCE strategic industrial innovation project on elastography-guided ultrasound therapy DEBT [4 years]
Theraclion 2008 .00 1st round-financing (follow-up) : 1.6 M€, by Truffle Venture RFINA [3 years]
Theraclion 2007 .12 Financing (no interest loan) : 1.3 M€ from OSEO Innovation (together with CE Mark approval) DEBT [3 years]
Theraclion 2006 .03 Clinical trial (phase II) for a non-invasive treatment of thyroid nodules (beginning) CLIN [1 year]
Theraclion 2005 .04 1st round-financing : 3.5 M€, by Truffle Venture RFINA [0 year]
Theraclion 2004 .08 Company founded by François Lacoste (CEO), Gérard Hascoët [Promed, Sometec, IMMI, Technomed International], Jean Louis Hervy [Sapex, SMI], Annie Claude Benichou [M.D.], Guillaume Olivier Doré ORGF [0 year]
Theradiag 2013 .04 Financing (no interest loan) : 1.2 M€ from OSEO Innovation (on 4 new diagnostic test within the 18 M€ project labelled CaReNa) DEBT [26 years]
Theradiag 2012 .12 Listing on Euronext : 8.2 M€ (IPO), extended to 8.6 M€ in January 2013 PBO [25 years]
Theradiag 2012 .07 Acquisition of Prestizia and its microRNA technology platform (presided by Jean-Jacques Bertrand) ACQ+ [25 years]
Theradiag 2012 .05 Company rename as Theradiag (from BioMedical Diagnostics or BMD) with no change in capital structure ORGL [25 years]
Theradiag 2011 .01 Nomination : Michel Finance as CEO (replacing Paul Magrez) ORGN [23 years]
Theradiag 2010 .03 Partnering distribution agreement from Assuragen (USA) to commercialize its Signature Oncology Products in France MKTG [23 years]
Theradiag 2009 .12 4th round-financing : 3.0 M€ by Truffle Venture and AGF P.E. RFIND [22 years]
Theradiag 2008 .10 Financing (no interest loan) : 5.4 M€ (and 2.5 M€ grant), OSEO Innovation, to support Tracker, a theranostics project concerning rheumatoid arthritis from Neovacs (leader) and Biomedical Diagnostics DEBT [21 years]
Theradiag 2007 .00 Nomination : Paul Magrez, as CEO (replacing Patrick G. Poty) ORGN [19 years]
Theradiag 2005 .07 3rd round-financing : 5.0 M€, led by Truffle Venture and CDC Entreprise, with AGF P.E., Siparex, Auriga Partners, Ventech, 123 Multinova RFINC [18 years]
Theradiag 2004 .05 Nomination : Patrick G. Poty, as CEO (Daniel Pierron on leave) ORGN [17 years]
Theradiag 2003 .05 2nd round-financing : 9.4 M€, by undisclosed investors RFINB [16 years]
Theradiag 2000 .05 1st round-financing : 4.6 M€, by undisclosed investors RFINA [13 years]
Theradiag 1987 .02 Company founded by 2 ex-Abbott managers, as BioMedical Diagnostics ORGF [0 year]
Theralpha 2011 .09 Partnering research agreement with Synprosis and IPMC for preclinical development of a cobra snake venom derivative R&D [2 years]
Theralpha 2011 .02 Financing (no interest loan) : 1.0 M€ from RDI/OSEO, for the preclinical development of a drug candidate for the treatment of pain DEBT [1 year]
Theralpha 2010 .10 Financing (no interest loan) : 1.0 M€ from OSEO, for THA901 DEBT [1 year]
Theralpha 2009 .04 Company founded by Michel Ladzunski, Marc Vasseur (born 1949) and David Dellamonica, as a spin-off of IPMC (Institut de Pharmacologie Moléculaire et Cellulaire) ORGF [0 year]
TheraVectys 2012 .09 Round financing : 7.5 M€ by private investors (Guy Paillaud, ex-Promodes, John Pieters, ex-Amgen, the Tethys fund of Bettencourt family, Philippe Oddo and Richard Hennessy) RFIN [7 years]
TheraVectys 2011 .05 Web site available, but with no news available INFO [6 years]
TheraVectys 2005 .05 Company founded by Dr Pierre Charneau, as a spin-off from Institut Pasteur (Paris) ORGF [0 year]
Transgene 2012 .09 Clinical trial (phase II) for JX594/TG6006 in Sorafenib-Refractory Liver Cancer Patients with Jennerex (interim, positive) CLIN [33 years]
Transgene 2011 .05 Partnering development agreement with Innate Pharma for immunomonitoring services, with set-up of new company named Platine Pharma Services R&D [32 years]
Transgene 2011 .03 Clinical trial (phase II) for TG4040 in chronic hepatitis C (recruitment completed, 154 patients) CLIN [32 years]
Transgene 2011 .01 Partnering development agreement with Beckman Coulter for a companion diagnostic test for TG4010 R&D [32 years]
Transgene 2010 .09 Partnering distribution agreement (also co-development) with Jennerex (USA) for Europe, CEI and Middle-East markets (exclusive distributor), concerning JX-594 (anticancer), along minorty share worth 3.8 M€ MKTG [31 years]
Transgene 2010 .05 Public (and private) offering : 152 M€ millions d'euros (Institut Mérieux maintain 55.2 % of shares, as first stakeholder) PBO [31 years]
Transgene 2010 .03 Licensing-out (exclusive option) of TG4010, for the first-line treatment of non-small cell lung cancer (NSCLC) and other potential cancer indications, to Novartis (10 MUS$ non-refundable option fee) LICOUT [31 years]
Transgene 2009 .12 Designation of Fast Track Status by FDA for TG4010, a targeted immunotherapy for treatment of Non-Small Cell Lung Cancer MKTG [30 years]
Transgene 2009 .05 Launch of Platine, a joint immuno-monitoring platform, by 5 partners (Innate Pharma, Transgene, ImmunID, Inserm and Cancer Centre Léon-Bérard), based in Lyon MKTG [30 years]
Transgene 2007 .06 Public offering : 100.1 M€ PBO [28 years]
Transgene 2007 .04 Licensing-out of HPV vaccine lead to Roche (terminated in February 2011) LICOUT [28 years]
Transgene 2006 .07 Public offering : 14.3 M€, through exercise of warrants PBO [27 years]
Transgene 2005 .06 Public offering : 34.9 M€, with refocus on therapeutic vaccines PBO [26 years]
Transgene 2004 .12 Nomination : Philippe Archinard as CEO ORGN [25 years]
Transgene 2002 .07 Nomination : Jean-François Carmier as CEO [ex-Transgene V.P.] ORGN [23 years]
Transgene 2001 .09 Management restructuring : 30 heads employee reduction from 195 headcounts ORGR [22 years]
Transgene 2001 .05 Public offering : 63.0 M€ in depositary shares for Biomérieux-Pierre Fabre and AFM (French Muscular Dystrophy Association), with refocus on cancer treatments PBO [22 years]
Transgene 2000 .11 Nomination : Gilles Bélanger [ex-Biomérieux], as CEO ORGN [21 years]
Transgene 1998 .03 Listing on Paris Nouveau Marché and New York Nasdaq : 100 MUS$ (about 80 M€) PBO [19 years]
Transgene 1995 .00 Production : GMP manufacturing facility completed INDUS [15 years]
Transgene 1992 .00 Nomination : Bernard Gilly as CEO, with refocus on gene transfer technology ORGN [12 years]
Transgene 1979 .00 Company founded by Pierre Chambon (Ph.D., CNRS, Research Director at Pasteur Institute) and others ORGF [0 year]
Trophos 2012 .10 Clinical trial (Phase II) on TRO40303, in acute myocardial infarction (beginning) CLIN [13 years]
Trophos 2012 .06 Nomination : Christine Placet (previously CFO, since 2004), as CEO (Damian Marron on leave) ORGN [13 years]
Trophos 2010 .12 Financing : leader of new MitoCare consortium awarded 6 M€ by EU for POC study of novel cardioprotective compound, TRO40303 RFIN [11 years]
Trophos 2010 .10 Clinical trial (Phase I) on TRO40303, in myocardial infarction (beginning), ended in February 2011 CLIN [11 years]
Trophos 2010 .09 Financing : 10.0 M€ from Actelion (Switzerland) against minority share, with rights of full acquisition up to 2012 depending on phase III clinical results of olesoxime RFIN [11 years]
Trophos 2010 .03 Clinical trial (phase III) for olesoxime in Amyotrophic Lateral Sclerosis (Lou Gehrig's disease) (end recruitment, results in December 2012, not superior to riluzole alone) CLIN [11 years]
Trophos 2010 .03 Launch : new web site on Charcot disease for patients and health professionals at MitoTarget MKTG [11 years]
Trophos 2009 .09 Clinical trial planned, after first preclinical trial results on TRO40303, a novel TSPO ligand, significantly reducing myocardial infarct size CLIN [10 years]
Trophos 2009 .03 Financing (grant over 3 years) : 6.7 M€ by Association Française contre les Myopathies (AFM), for further clinical development of lead drug candidate olesoxime (TRO19622) as a treatment for Spinal Muscular Atrophy RFIN [10 years]
Trophos 2008 .12 Financing (no interest loan) : 6.0 M€, by the European Commission, to boost TRO19622 programs for ALS, within Trophos led consortium (Mitotarget) DEBT [9 years]
Trophos 2008 .06 Nomination : Damian Marron as CEO, replacing co-founder Antoine Béret [born 1944, ex-Immunotech] who retires ORGN [9 years]
Trophos 2008 .02 Financing (no interest loan) : 1.0 M€, by ANR, to support the project named IRIstop DEBT [9 years]
Trophos 2007 .09 3rd round-financing : 8.5 M€, led by OTC Asset Management with CM-CIC Asset Management and previous shareholders RFINC [8 years]
Trophos 2003 .04 2nd round-financing : 6.4 M€, led by Innoveris and previous shareholders RFINB [4 years]
Trophos 1999 .01 Company founded by Antoine Béret (CEO), Michel Deléage (venture capitalist, died in 2011), and 3 scientists (as consultants) ORGF [0 year]
TxCell 2011 .06 Clinical trial (phase IIb) for OvaSave in Crohn's Disease (beginning, extension of CATS1 phase I/II) CLIN [10 years]
TxCell 2011 .03 Nomination : François Meyer, as CEO (replacing Frédéric Hammel, following a legal decision of backup procedure) ORGN [9 years]
TxCell 2010 .04 Clinical trial (phase II) for OvaSave in Crohn's Disease (positive preliminary results) CLIN [9 years]
TxCell 2008 .03 2nd round-financing : 10.5 M€, by previous shareholders RFINB [6 years]
TxCell 2006 .00 Nomination : Frédéric Hammel [born 1966], as CEO (H. Groux in supervisory board) ORGN [4 years]
TxCell 2004 .10 1st round-financing : 10.5 M€, by Auriga Partners, AXA Private Equity, BioAm, CDC and SPEF Venture RFINA [3 years]
TxCell 2004 .00 Nomination : Philippe Ballero [ex-Yamanouchi, Proskelia], as CEO ORGN [2 years]
TxCell 2001 .04 Company founded by Dr Hervé Groux [CSO, ex-Inserm, CNRS] and Dr Françoise Cottrez, within Nice Archet Hospital, as a spin-off from Inserm ORGF [0 year]
UroGenelégende 2008 .10 Research : development of new experimental models for stress or mixed urinary incontinence R&D [4 years]
UROsphere 2007 .02 Research : development of new experimental models for OverActive Bladder (OAB) and for Painful Bladder Syndrome (PBS) R&D [2 years]
UROsphere 2004 .08 Company founded by Philippe Lluel and Stefano Palea, as a spin-off from Sanofi-Synthelabo ORGF [0 year]
Vaxon Biotechlégende 2011 .08 Research : 2 publication in Cancer Immunology Immunotherapy and in Annals of Oncology presenting immunological and clinical data in cancer patients vaccinated with Vx-001 R&D [7 years]
Vaxon Biotech 2010 .05 Clinical trial (phase II) for Vx-001 therapeutic vaccine (end) CLIN [6 years]
Vaxon Biotech 2010 .02 Registration : orphan Drug designation by FDA for Vx-001 in the treatment of NSCLC MKTG [6 years]
Vaxon Biotech 2009 .00 Nomination : François Vallet, as CEO, replacing Philippe Berthon ORGN [4 years]
Vaxon Biotech 2007 .11 Registration : orphan Drug designation by EMEA for Vx-001 in NSCL cancer MKTG [3 years]
Vaxon Biotech 2006 .00 Company move from Evry Genopole to Paris ORGL [1 year]
Vaxon Biotech 2004 .12 Clinical trial (phase I) for Vx-001 (beginning, proof of principle) CLIN [0 year]
Vaxon Biotech 2004 .06 Company founded by Dr Kostas Kosmatopoulos, Inserm, with Philippe Berthon [Ph.D.] nominated as CEO, located at Evry Genopole ORGF [0 year]
Vectalys 2007 .08 Partnering research agreement with Pierre Fabre R&D [2 years]
Vectalys 2005 .07 Company founded by Pascale Bouillé ORGF [0 year]
Vivalislégende 2012 .12 Acquisition of Intercell (Austria), by merger with name change of new company as Valneva ACQ+ [13 years]
Vivalis 2011 .07 Partnering commercial agreement with Transgene, on EB66 cell line for the manufacturing of Transgene MVA-based therapeutic vaccines MKTG [12 years]
Vivalis 2010 .09 Partnering research agreement with Mymetics (Switzerland), to evaluate the replication of an undisclosed virus in EB66 cell line for the manufacturing of human vaccines R&D [11 years]
Vivalis 2010 .07 Round financing : 30.0 M€ through capital increase from Grimaud (15.5 M€), indirectly derived from FSI grant RFIN [11 years]
Vivalis 2010 .06 R&D : new laboratory unit with a new building (3300 square meters), near Nantes INDUS [11 years]
Vivalis 2010 .01 Acquisition of Humalys, a private French biotech R&D company, based in Lyon, specialised in the generation of human monoclonal anti-bodies ACQ+ [10 years]
Vivalis 2009 .01 Partnering research agreement with Innate Pharma to produce IPH 4101 with EB66 for clinical trials (Oseo debt financing grant of 3.0 M€ for Vivalis) R&D [9 years]
Vivalis 2008 .10 Licensing-out of EB66 cell line to CSL to test for the development and manufacturing of a therapeutic protein candidate LICOUT [9 years]
Vivalis 2007 .06 Listing on Euronext : 29.0 M€ PBO [8 years]
Vivalis 2005 .00 Production : new manufacturing unit with a new building (1500 square meters), near Nantes INDUS [5 years]
Vivalis 2004 .11 2nd round-financing : 5.3 M€, by Grimaud Group, FCJE (CDC), Créagro, Pays de la Loire Développement, and banks, to finance the buiding of a manufacturing unit RFINB [5 years]
Vivalis 2003 .00 Partnering development with undisclosed company on Ebx cells R&D [3 years]
Vivalis 1999 .06 1st round-financing : 4.6 M€, by Grimaud Group RFINA [0 year]
Vivalis 1999 .04 Company founded by Grimaud Group (Franck Grimaud), based on research know-how by Dr Bertrand Pain and Dr Jacques Samarut ORGF [0 year]
XenTechlégende 2012 .11 Expansion of patient-derived tumor xenograft collection with new renal carcinoma PDX models R&D [6 years]
XenTech 2009 .05 Nomination : Bertrand Coulomb, new CEO, Jean-Gabriel Judde, founder, still chairman ORGN [3 years]
XenTech 2008 .10 1st round-financing : 0.6 M€, by Aurinvest Capital 2 RFINA [2 years]
XenTech 2006 .04 Company founded by Jean-Gabriel Judde, Pascal Leuraud, Marie-France Poupon, Arnaud Beurdeley, as a spin-off from Institut Curie ORGF [0 year]
Adiatec ǂ 2005 .12 Company liquidation INFO [7 years]
Adiatec ǂ 1998 .01 Company founded by Joël Lesser ORGF [0 year]
Alphelys ǂ 2011 .02 Company liquidation INFO [9 years]
Alphelys ǂ 2009 .12 Partnering distribution agreement with Biogen (USA) for Brazil market (exclusive distributor) MKTG [8 years]
Alphelys ǂ 2008 .05 Partnering distribution agreement with Zytomed Systems (Germany) for immunohistochemical reagents in France MKTG [6 years]
Alphelys ǂ 2006 .10 Partnering distribution agreement with Seroa (Monaco) for product portfolio in many countries worldwide MKTG [5 years]
Alphelys ǂ 2005 .06 Seed financing : 0.24 M€, by owners, as a capital increase from 0.16 M€ to 0.40 M€ SFIN [3 years]
Alphelys ǂ 2002 .02 Company name change from Amelys to Alphelys, due to pre-occupied name INFO [0 year]
Alphelys ǂ 2001 .10 Company founded by Pierre Chaumat and Pierre Defrenaix (initially named Amelys) ORGF [0 year]
Aptanomics ǂ 2007 .07 Financial complete burn-out and bankruptcy INFO [6 years]
Aptanomics ǂ 2006 .11 Divestiture of some R&D assets to Imaxio (UK) LICOUT [5 years]
Aptanomics ǂ 2005 .06 Partnering research agreement with Boehringer-Ingelheim in aptamer-based target validation R&D [4 years]
Aptanomics ǂ 2003 .05 Nomination : Michael Courtney [ex-Transgene], as CEO ORGN [2 years]
Aptanomics ǂ 2002 .11 1st round-financing : 7 M€, by AGF P.E., CDC Ixis, Ventech RFINA [1 year]
Aptanomics ǂ 2001 .03 Company founded by John Hawken, Pierre Colas [Inserm, CSO], as a spin-off from Normale Sup (Lyon), based on patents from Massachusetts General Hospital ORGF [0 year]
Bionexis Pharmaceuticals ǂ 2004 .12 Company liquidation INFO [2 years]
Bionexis Pharmaceuticals ǂ 2004 .02 1st round-financing : 6 M€, led by Edmond de Rotschild I.P., with Bioam, Sophia Euro lab, FCJE (CDC), CEA RFINA [2 years]
Bionexis Pharmaceuticals ǂ 2004 .02 Company move from Saclay (CEA) to Paris (Biotech) RELOC [2 years]
Bionexis Pharmaceuticals ǂ 2002 .02 Company founded by Françoise Russo-Marie and Alain Samson ORGF [0 year]
Bionisis ǂ 2008 .03 Company liquidation INFO [8 years]
Bionisis ǂ 2002 .09 2nd round-financing : 2.5 M€ RFINB [2 years]
Bionisis ǂ 1999 .10 Company founded by unknown entrepreneurs ORGF [0 year]
Carex ǂ 2006 .05 Acquisition by 7TM Pharma (Denmark) ACQ- [5 years]
Carex ǂ 2004 .03 2nd round-financing : 25 M€, by Crédit Lyonnais P.E., Global Life Science Ventures, BioMedinvest, HBM, and previous shareholders RFINB [3 years]
Carex ǂ 2002 .07 Nomination : Geoffrey Race, as CEO [1 year]
Carex ǂ 2002 .04 1st round-financing : 6 M€, led by Sofinnova Partners, GIMV and Mara Ventures RFINA [1 year]
Carex ǂ 2001 .11 Company founded by Johan Auwerx, Pierre Chambon, Samir S. Deeb, Hana Koutnikova, Jürgen M.Lehmann, based on research from Institut de Génétique et de Biologie Moléculaire et Cellulaire, by Pierre Chambon (President of the board) ORGF [0 year]
Cellpep ǂ 2006 .03 Acquisition by Procyon (Canada), for 39 MUS$, to form a new legal entity, Ambrilia Biopharma (www.ambrilia.com) ACQ- [8 years]
Cellpep ǂ 2003 .03 Round-financing : 3.8 M€, by Turenne Capital Partenaires, OTC Asset Management, H2i Management, Synergènes RFIN [5 years]
Cellpep ǂ 1998 .00 Company founded by Bonabes de Rougé, Michel Mollard and others ORGF [0 year]
CellVir ǂ 2010 .11 Company struck off LEGAL [4 years]
CellVir ǂ 2008 .06 Seed financing : 2 M€, by Genopole 1er Jour and Inserm Transfert Initiative SFIN [2 years]
CellVir ǂ 2006 .08 Patent : granted from Inserm (spin-off) LEGAL [0 year]
CellVir ǂ 2006 .03 Company founded by Richard Benarous, Richard Platford, Armand Frydman, E.Thomas Bader, Jean Deregnaucourt ORGF [0 year]
Celogos ǂ 2006 .01 Acquisition by HRA Pharma of majority share, with Celogos maintained as a French subsidiary and Christian Pinset as CSO ACQ- [4 years]
Celogos ǂ 2005 .11 Partnering research agreement, HRA Pharma, for pharmaceutical development process of future lead compounds R&D [4 years]
Celogos ǂ 2001 .08 Company founded by Christian Pinset, cell therapy expert and Didier Montarras (from Institut Pasteur, in Paris) ORGF [0 year]
Cezanne ǂ 2009 .12 Acquisition by Thermo Fisher Scientific (USA) ACQ- [9 years]
Cezanne ǂ 2009 .06 Partnering research agreement with Brahms (Germany) and Lumiphore (USA), with incorporation of Lumiphore's complexes into diagnostic tests R&D [9 years]
Cezanne ǂ 2003 .09 Partnering sales agreement with Brahms (Germany) as exclusive distributor MKTG [3 years]
Cezanne ǂ 2003 .09 Company move to Nîmes, after floods devastated the initial premises in September 2002 ORGL [3 years]
Cezanne ǂ 2000 .06 Company founded by Emmanuel Bois and others, in Bagnols-sur-Cèze, to continue the divested diagnostics activities by CisBio International, after their acquisition by Schering AG ORGF [0 year]
Cytomics ǂ 2010 .12 Company liquidation INFO [10 years]
Cytomics ǂ 2008 .03 Company move to Orsay (from nearby Gif-sur-Yvette) and rename as Cytomics Pharmaceuticals (from Cytomics Systems) ORGL [7 years]
Cytomics ǂ 2007 .10 Financing (no interest loan) : 2.1 M€, by OSEO, to support its ongoing program in the anti-fungal area (second Oseo grant) DEBT [7 years]
Cytomics ǂ 2007 .03 Nomination : Bernard Cambou, new CEO, Prof. Dominique Thomas, founder, resigns ORGN [6 years]
Cytomics ǂ 2006 .02 2nd round-financing : 10.0 M€, by Edmond de Rotschild I.P., Truffle Venture and previous shareholders RFINB [5 years]
Cytomics ǂ 2003 .02 1st round-financing : 3.0 M€, by Société Générale A.M., and others RFINA [2 years]
Cytomics ǂ 2000 .04 Company founded by Dominique Thomas, at initially, Gif-sur-Yvette (near Paris), in collaboration with Richard Benarous (initially as Cytomics Systems, then from February 2008, as Cytomics Pharmaceuticals) ORGF [0 year]
Diatos ǂ 2009 .05 Company bankruptcy (in need of € 10 Million re-financing), then liquidation INFO [10 years]
Diatos ǂ 2008 .12 Licensing-out of DTS-108, a pro-drug of irinotecan to Drais (with co-development) LICOUT [9 years]
Diatos ǂ 2008 .08 Clinical trial (phase IIa) for DTS-201, a peptidic prodrug of doxorubicin (beginning) CLIN [9 years]
Diatos ǂ 2007 .07 4th round-financing : 9.4 M€, by Credit Agricole P.E. and previous shareholders RFIND [8 years]
Diatos ǂ 2006 .07 Listing : failure of IPO introduction on Alternext, cancelled due to unfavorable market conditions PBO [7 years]
Diatos ǂ 2006 .05 Licensing-in of specialty cancer product from Gilead LICIN [7 years]
Diatos ǂ 2005 .04 Set-up of US subsidiary in California, USA (Business) ORGC [6 years]
Diatos ǂ 2004 .03 Set-up of subsidiary in Leuven, Belgium (R&D) ORGC [5 years]
Diatos ǂ 2004 .02 3rd round-financing : 7.0 M€, by Innoven and BFF (Biotech Fund Flanders) RFINC [5 years]
Diatos ǂ 2003 .05 2nd round-financing : 9.0 M€, by NIF and Crédit Lyonnais P.E. (today Crédit Agricole P.E.) RFINB [4 years]
Diatos ǂ 2003 .04 Licensing-out of cancer improved-delivery drug development to Medarex LICOUT [4 years]
Diatos ǂ 2000 .10 1st round-financing : 15.5 M€, led by GIMV and InterWest Partners, with Société Générale A.M., AGF P.E., Sopartec, Sofinnova Partners RFINA [1 year]
Diatos ǂ 1999 .05 Seed financing : 1.5 M€, by Sofinnova Partners (subsequently John Tchelingerian joins the company as business developper) SFIN [0 year]
Diatos ǂ 1999 .02 Company founded by Prof. Stratis Avraméas, Dr Thérèse Ternynck, as a spin-off from Institut Pasteur ORGF [0 year]
Drugabuse Sciences ǂ 2008 .05 Company liquidation : legal dissolution INFO [10 years]
Drugabuse Sciences ǂ 2007 .01 Divestiture of assets (product portfolio, including naltrexone) to Elbion (Belgium) for undisclosed terms ACQ- [9 years]
Drugabuse Sciences ǂ 2006 .06 Listing on Alternext processed : 20 M€ expected (failed) PBO [8 years]
Drugabuse Sciences ǂ 2004 .01 Acquisition of mother US company by French subsidiary, with new CEO (Robert Floch) and 4.0 M€ convertible loan by CDC Ixis ACQ+ [6 years]
Drugabuse Sciences ǂ 2001 .04 Round-financing : 27.0 M€, by Canaan Partners, Bionex, Jalla Equities, Palldin Group, 3i, ABN Amro, Ace Management RFIN [3 years]
Drugabuse Sciences ǂ 1999 .10 Round-financing : 21.0 M€, by 3i, ABN Amro, Auriga, CDC Innovation, Financière de Brienne, Nomura, Parnib, Partech, Rothschild Asset Management, Société Générale A.M. RFIN [1 year]
Drugabuse Sciences ǂ 1997 .12 Company founded by Philippe Pouletty (today Truffle Ventures), with name also shortened as DAS ORGF [0 year]
EchoSens ǂ 2011 .03 Acquisition by Inner Mongolia Free Han & Mongolia Pharmaceuticals (China), for undisclosed sum ACQ- [9 years]
EchoSens ǂ 2008 .12 Nomination : Richard Guillaume, new CEO, replacing Bertrand Fourquet ORGN [7 years]
EchoSens ǂ 2007 .00 Set-up of 3 subsidiaries in Spain, Germany and China, more than 330 FibroScan® installed worldwide ORGC [5 years]
EchoSens ǂ 2004 .00 Round-financing : undisclosed M€, by OTC and Cap Décisif, beginning of the commercialization of FibroScan with dedicated probe in France RFIN [2 years]
EchoSens ǂ 2003 .11 CE mark obtained for FibroScan MKTG [2 years]
EchoSens ǂ 2001 .06 Company founded by Sylvain Yon [born 1974], Bertrand Fourquet [Essec, as CEO], Laurent Sandrin, Jean-Michel Hasquenoph [ESTP], supported by ANVAR ORGF [0 year]
EndoCells ǂ 2008 .05 Acquisition by Esperante Ventures (Holland) ACQ- [3 years]
EndoCells ǂ 2004 .08 Company founded by Prof. Paul Czernichow [M.D. pediatry], Raphaël Scharfmann [Inserm] ORGF [0 year]
Fovea Pharmaceuticals ǂ 2009 .10 Acquisition by Sanofi Aventis (France), for 370 M€ (maximum, depending on milestones) ACQ- [4 years]
Fovea Pharmaceuticals ǂ 2009 .05 Clinical trial (proof-of-concept, positive) for Prednisporin (FOV1101) in patients with persistent allergic conjunctivitis CLIN [4 years]
Fovea Pharmaceuticals ǂ 2009 .02 Licensing-in of European rights of an ocular formulation of DX-88 for the treatment of retinal diseases from Dyax LICIN [3 years]
Fovea Pharmaceuticals ǂ 2007 .12 2nd round-financing : 30.0 M€, by previous shareholders RFINB [2 years]
Fovea Pharmaceuticals ǂ 2007 .11 Partnering research agreement with Genzyme R&D [2 years]
Fovea Pharmaceuticals ǂ 2005 .11 1st round-financing : 20.5 M€, by Sofinnova Partners, CAPE, Abingsworth Management, The Wellcome Trust, GIMV RFINA [0 year]
Fovea Pharmaceuticals ǂ 2005 .05 Company founded by Bernard Gilly, Pierre Bélichard, Prof. José-Alain Sahel (professor, Ophthalmology), based on platform from INSERM research unit 592 ORGF [0 year]
GenOdyssee ǂ 2010 .10 Company liquidation INFO [11 years]
GenOdyssee ǂ 2008 .02 Patent : notice of Allowance of US Application for lead compound (Interferon alpha variant 17) LEGAL [8 years]
GenOdyssee ǂ 2006 .10 Partnering research agreement with Baxter on therapeutic proteines derived from natural genetiques variations R&D [7 years]
GenOdyssee ǂ 2000 .05 1st round-financing : 8.1 M€, led by Matignon I.F., with Edmond de Rotschild Fin., Société Générale A.M., George Cohen RFINA [0 year]
GenOdyssee ǂ 1999 .10 Company founded by Jean-Louis Escary (the first company incubated at Evry Genopole) ORGF [0 year]
Génopoïetic ǂ 2008 .11 Nomination : François R. Martelet (Avax CEO since 2007) as President, and Isabelle Fourthin as Managing Director ORGN [14 years]
Génopoïetic ǂ 2000 .08 Acquisition by Avax Technologies, Philadelphia (USA) ACQ- [6 years]
Génopoïetic ǂ 1994 .11 Round-financing : undisclosed M€, by Rhône-Poulenc Rorer (France), against a minority share to support gene therapy trials RFIN [0 year]
Génopoïetic ǂ 1993 .12 Company founded by David Klatzmann and Jean-Loup Salzmann with the support of UPMC (Université Pierre et Marie Curie), with Charles Salzmann as CEO ORGF [0 year]
Genset ǂ 2002 .06 Acquisition by Serono (Switzerland) [today Merck-Serono] ACQ- [13 years]
Genset ǂ 1996 .06 Listing on Nasdaq : 100 MUS$ (about 80 M€) PBO [7 years]
Genset ǂ 1989 .00 Company founded by Marc Vasseur (a leading French scientist), Pascal Brandys (CEO, venture capitalist) ORGF [0 year]
Hemosystem ǂ 2006 .10 Company liquidation INFO [7 years]
Hemosystem ǂ 2004 .09 Round-financing : 3.0 M€, by FCJE (CDC), and previous shareholders RFIN [5 years]
Hemosystem ǂ 1999 .05 Company founded by Jean-Pierre Hermet (CEO) ORGF [0 year]
IDM Pharma ǂ 2009 .05 Acquisition by Takeda, for US$ 75 Million ACQ- [22 years]
IDM Pharma ǂ 2008 .02 Partnering research agreement ended with Sanofi-Aventis, after disappointing results on Junovan R&D [21 years]
IDM Pharma ǂ 2007 .06 Nomination : Timothy Walbert, new CEO and Chairman, with resignation by founder Jean-Loup Romet-Lemonne ORGN [20 years]
IDM Pharma ǂ 2005 .03 Acquisition by Epimune, as a merger with name change from IDM to IDM-Pharma ACQ- [18 years]
IDM Pharma ǂ 2002 .12 Round-financing : 20.0 M€, by Sanofi-Synthelabo (exclusive, shareholding : 11%) RFIN [15 years]
IDM Pharma ǂ 2002 .01 Partnering research agreement with Sanofi-Synthelabo R&D [15 years]
IDM Pharma ǂ 2000 .11 Round-financing: 48.9 M€ RFIN [13 years]
IDM Pharma ǂ 1993 .12 Company founded by Jean-Loup Romet-Lemonne (as Immuno-Designed Molecules, IDM) ORGF [6 years]
Ivagen ǂ 2008 .07 Company liquidation INFO [6 years]
Ivagen ǂ 2007 .04 Round-financing : undisclosed M€, by Matignon I.G., OTC Asset Management (after receivership in 2004) RFIN [5 years]
Ivagen ǂ 2002 .02 Company founded by Jean-Claude Aziza (unexpectedly deceased in 2006), Gilbert Skorski ORGF [0 year]
LibraGen ǂ 2010 .12 Acquisition by Induchem (Switzerland) ACQ- [9 years]
LibraGen ǂ 2010 .04 Launch of NovHyal, a new cosmetic formulation in S3D regenerative serum MKTG [9 years]
LibraGen ǂ 2010 .01 Sustainable process intensification in the manufacturing of its cosmetic actives, Inoveol MKTG [8 years]
LibraGen ǂ 2008 .12 Launch of Inoveol (www.inoveol.com) actives (stable polyphenol cosmetic compounds) on the US market MKTG [7 years]
LibraGen ǂ 2008 .09 Partnering research agreement with DSM, to co-develop transaminases for production of chiral amines R&D [7 years]
LibraGen ǂ 2006 .01 Partnering research agreement with Pierre Fabre, enzymatic synthesis R&D [4 years]
LibraGen ǂ 2005 .11 Partnering research agreement with Minakem on biocatalysis and organic synthesis (green chemistry, fine chemicals) R&D [4 years]
LibraGen ǂ 2005 .06 Nomination : Fabrice Lefèvre, as CSO ORGN [4 years]
LibraGen ǂ 2004 .09 Company move from Lyon to Toulouse ORGL [3 years]
LibraGen ǂ 2004 .05 1st round-financing : 2.2 M€, by BIOAM, Galia Gestion, and IRDI (Midi Pyrénées V.C.) RFINA [3 years]
LibraGen ǂ 2001 .03 Seed financing : 0.75 M€, by Bioam SFIN [0 year]
LibraGen ǂ 2001 .02 Company founded by Renaud Nalin and Pascal Simonet [CNRS] in Lyon ORGF [0 year]
MicroBioChips ǂ 2010 .09 Acquisition by BioSystems International (by partial transfer of assets of MBC to BSI) with company struck off on August 17. 2011 ACQ- [4 years]
MicroBioChips ǂ 2010 .02 Licensing-in of PlasmaScan antibody microarray products that speed-up identification of human plasma biomarkers from Biosystems LICIN [3 years]
MicroBioChips ǂ 2009 .01 Partnering marketing agreement (worldwide) with Abcam on custom antibody arrays MKTG [2 years]
MicroBioChips ǂ 2008 .08 Company move from Evreux to Paris with 10 times more space ORGL [2 years]
MicroBioChips ǂ 2008 .07 Set-up of UK subsidiary in London (led by Pascal Azabian) ORGC [2 years]
MicroBioChips ǂ 2008 .06 Certification : ISO 9001-2000 INFO [2 years]
MicroBioChips ǂ 2007 .02 Partnering distribution agreement with Vigene Tech, for the US market MKTG [0 year]
MicroBioChips ǂ 2006 .05 Company founded by Dr Vincent Saulot and Pascal Azabian, based in Evreux incubator ORGF [0 year]
Meristem Therapeutics ǂ 2008 .08 Company liquidation INFO [10 years]
Meristem Therapeutics ǂ 2007 .10 Court : applications on appeal for GMO corn testing, rejected by tribunal LEGAL [9 years]
Meristem Therapeutics ǂ 2004 .02 Nomination : Jean-Paul Rohmer, chairman of Supervisory Board ORGN [5 years]
Meristem Therapeutics ǂ 2002 .06 4th round-financing : 21.5 M€, by AGF P.E., Antin Innovation, CPR P.E., Innoven, Edmond de Rotschild I.P., Odyssée Ventures, Pechel Industrie, SPEF, and previous shareholders RFIND [4 years]
Meristem Therapeutics ǂ 2001 .07 Listing : failure of IPO introduction due to unfavorable financial environment for 54 M€ expected PBO [3 years]
Meristem Therapeutics ǂ 2000 .11 Acquisition of Sedaherb, phyto-subcontractor to pharmaceutical industry, for around 1 year turnover, 3.5 M€ ACQ+ [2 years]
Meristem Therapeutics ǂ 2000 .06 3rd round-financing : 10.0 M€, by BNP, Tethys, 3i, Sofipar, Sofimac RFINC [2 years]
Meristem Therapeutics ǂ 1999 .02 2nd round-financing : 18.3 M€, by Banexi Ventures 2, Banexi, 3i, Sofimac (Société de Financement du Massif Central), Sofipar (groupe Crédit Agricole) and capital disposal by Limagrain to the financial investors RFINB [0 year]
Meristem Therapeutics ǂ 1998 .05 1st round-financing : 10.0 M€, by Limagrain RFINA [0 year]
Meristem Therapeutics ǂ 1998 .04 Company founded by Limagrain (Agro-food cooperative company, the number one seed producer in Europe), based on an innovative technology (Molecular Pharming) developped since 1992 ORGF [0 year]
MitoProd ǂ 2011 .03 Company liquidation INFO [6 years]
MitoProd ǂ 2009 .03 Partnering distribution agreement with Sigma-Aldrich for Customized Long RNA Oligonucleotides MKTG [4 years]
MitoProd ǂ 2009 .01 Patent : granted on new class of interfering RNA, called ciRNA (circularization of the active molecules) LEGAL [4 years]
MitoProd ǂ 2008 .02 Partnering distribution agreement with Eurobio Labs for European market MKTG [3 years]
MitoProd ǂ 2006 .05 1st round-financing : 1.6 M€, by undisclosed investors RFINA [1 year]
MitoProd ǂ 2005 .05 Seed financing : 0.14 M€, by Aquitaine Création Innovation SFIN [0 year]
MitoProd ǂ 2004 .09 Company founded by Guillaume Plane (CEO), Nathalie Bonnefoy [CNRS], based on a technology discovered by Dr. Jean-Paul di Rago [CNRS, also co-founder] ORGF [0 year]
Mutabilis ǂ 2010 .06 Company struck off LEGAL [8 years]
Mutabilis ǂ 2009 .06 Acquisition by start-up Pharma Omnium International (France), with company name maintained and Stéphane Huguet (Président POI), back as CEO ACQ- [7 years]
Mutabilis ǂ 2007 .10 Nomination : Stephan Fischer as CEO ORGN [6 years]
Mutabilis ǂ 2005 .04 Partnering research agreement with Chiron (today Novartis) to develop new generation of prophylactic vaccines R&D [3 years]
Mutabilis ǂ 2004 .06 2nd round-financing : 8.0 M€, by Auriga Partners, Crédit Lyonnais P.E. (today Crédit Agricole P.E.), and previous shareholders RFINB [2 years]
Mutabilis ǂ 2002 .07 1st round-financing : 2.0 M€, by Bioam, AXA P.E., Inserm-Transfert RFINA [0 year]
Mutabilis ǂ 2002 .03 Nomination : Stéphane Huguet [ex-Pharmacia, Phoenix, Fournier, Sandoz] as CEO ORGN [0 year]
Mutabilis ǂ 2001 .08 Company founded by Prof. Xavier Nassif, as a spin-off from Inserm ORGF [0 year]
Myosix ǂ 2011 .02 Company liquidation INFO [10 years]
Myosix ǂ 2010 .09 Nomination : Christian Deleuze as CEO ORGN [10 years]
Myosix ǂ 2010 .02 Patent : granted in EU, for MX' technology, on new class of interfering RNA, called ciRNA (circularization of the active molecules) LEGAL [9 years]
Myosix ǂ 2008 .09 Certification : cell therapy laboratory as an authorized center to prepare Cell Therapy Product of clinical use, by AFSSAPS INFO [8 years]
Myosix ǂ 2008 .04 Partnering manufacturing agreement with Association Française contre les Myopathies (AFM, i.e. French Muscular Dystrophy Association) to support research on muscular pathologies and cell therapy INDUS [7 years]
Myosix ǂ 2007 .04 Production : cell therapy (beginning) in Saint Louis hospital (Paris) INDUS [6 years]
Myosix ǂ 2002 .11 Clinical trial (phase II) for cell therapy (beginning, first worldwide) CLIN [2 years]
Myosix ǂ 2002 .07 Partnering research agreement with Genzyme, including capital sharing (49%) R&D [1 year]
Myosix ǂ 2000 .09 Company founded by Dr Jean-Thomas Vilquin, Prof. Jean-Pierre Marolleau and Dr Scorsin, from a patent application on myoblast production technology filed by AP-HP, AFM (French Muscular Dystrophy Association) and INSERM ORGF [0 year]
Nautilus Biotech ǂ 2008 .11 Company liquidation INFO [8 years]
Nautilus Biotech ǂ 2007 .04 Clinical trial (phase I) for Belerofon in USA (beginning) CLIN [7 years]
Nautilus Biotech ǂ 2007 .04 4th round-financing : 8.4 M€, by Pre-IPO Invest, Auriga Partners, Matignon Tech, Edmond de Rothschild I.P., FCJE (CDC), 123 Ventures, Creabilis Therap. RFIND [7 years]
Nautilus Biotech ǂ 2007 .02 Partnering research agreement with Wyeth on hemophilia therapies R&D [7 years]
Nautilus Biotech ǂ 2005 .02 3rd round-financing : 7.25 M€, by Auriga Partners, Matignon Tech, Edmond de Rothschild I.P., FCJE (CDC), 123 Ventures, Creabilis Therap. RFINC [5 years]
Nautilus Biotech ǂ 2005 .02 Nomination : Philip Parkinson as CFO (then CEO, in 2007) ORGN [5 years]
Nautilus Biotech ǂ 2003 .10 Nomination : Reinhard Koenig [M.D.], as Vice President Clinical & Regulatory Affairs of Nautilus Biotech USA ORGN [3 years]
Nautilus Biotech ǂ 2000 .08 1st round-financing : 0.9 M€, by undisclosed investors RFINA [0 year]
Nautilus Biotech ǂ 2000 .01 Company founded by Dr Manuel Vega (CEO) et Paul Martin ORGF [0 year]
Neuro3D ǂ 2007 .03 Liquidation and divestiture of R&D assets to Evotec (Germany) INFO [6 years]
Neuro3D ǂ 2005 .05 Clinical trial (phase III) for key lead compound, ocaperidone, licensed to J&J (beginning) CLIN [4 years]
Neuro3D ǂ 2004 .12 4th round-financing : 31.5 M€, by previous shareholders RFIND [4 years]
Neuro3D ǂ 2003 .09 3rd round-financing : 10.0 M€, by previous shareholders RFINC [3 years]
Neuro3D ǂ 2003 .05 Acquisition of Neurofit (France), a biotech CRO ACQ+ [2 years]
Neuro3D ǂ 2002 .09 2nd round-financing : 20.0 M€, led by HealthCap, with Techno Venture Management and previous shareholders RFINB [2 years]
Neuro3D ǂ 2002 .03 Licensing-out of Ocaperidone to Janssen (J&J) LICOUT [1 year]
Neuro3D ǂ 2000 .11 1st round-financing : 7.6 M€, by founder V.C., Apax Partners RFINA [0 year]
Neuro3D ǂ 2000 .09 Company founded by Sofinnova, Charles Woler (CEO), Jean-Jacques Bourguignon, Jean-Paul Macher ORGF [0 year]
Neurotech ǂ 2006 .06 Company move from Paris to Delaware (USA), as the legal domicile, with change in nationality and website as www.neurotechusa.com ORGL [8 years]
Neurotech ǂ 2003 .11 4th round-financing : 12.0 M€, led by Apax Partners and Merlin Biosciences, with previous shareholders (3i Plc, GIMV, West LB, Atlas Venture and Ergo Equity) RFIND [5 years]
Neurotech ǂ 2002 .01 Licensing-in agreement of CNTF with Amgen in all ophthalmology indications LICIN [4 years]
Neurotech ǂ 2001 .05 3rd round-financing : 35.0 M€, led by Apax Partners and Merlin Biosciences with Westdeutsche Landesbank Girozentrale, ABN Amro, Rotschild, AGF Innovation, and previous shareholders (3I Plc, GIMV, Atlas Venture, CDC Innovation, Sofinnova, Sudinnova, Banque de Vizille, IMH) RFINC [3 years]
Neurotech ǂ 2000 .00 Set-up of US subsidiary in Lincoln ORGC [1 year]
Neurotech ǂ 1998 .10 Company founded by unknown entrepreneurs ORGF [0 year]
Novagali ǂ 2011 .09 Acquisition by Santen (preliminary approval to acquire 100% stake for 102 M€, finalized in December) ACQ- [11 years]
Novagali ǂ 2011 .08 Clinical trial (phase III) for Catioprost (completion, positive) CLIN [11 years]
Novagali ǂ 2011 .04 Clinical trial (phase III) for Cyclokat, a new formulation of Cyclosporine, in dry eye (beginning) CLIN [10 years]
Novagali ǂ 2011 .01 Registration : positive advice from EMA on Cyclokat Phase III clinical trial for the treatment of Dry Eye Disease MKTG [10 years]
Novagali ǂ 2010 .07 Listing on Euronext Paris : 22.0 M€ PBO [9 years]
Novagali ǂ 2010 .04 Financing (no interest loan) : 9.4 M€, by OSEO, as the lead project company (with Stanipharm, Crossject, and CNRS) on retinopathy for Vitrena DEBT [9 years]
Novagali ǂ 2009 .04 Clinical trial (phase II) for with Cyclokat, a new formulation of Cyclosporine, in dry eye (completion) CLIN [8 years]
Novagali ǂ 2009 .02 Research : positive in vivo toxicity evaluation of BAK-free latanoprost formulation for glaucoma R&D [8 years]
Novagali ǂ 2008 .12 Registration : provisionally negative opinion from EMEA for lead compound Vekacia (non convincing results : dossier is withdrawn) MKTG [8 years]
Novagali ǂ 2008 .09 4th round-financing : 15.0 M€, by previous shareholders RFIND [8 years]
Novagali ǂ 2008 .04 Launch of Cationorm on the French market, the first for the company MKTG [7 years]
Novagali ǂ 2007 .03 Clinical trial (phase III) for Vekacia in Vernal Keratoconjonctivitis (VKC) (completed, positive) CLIN [6 years]
Novagali ǂ 2006 .04 3rd round-financing : 26.0 M€, with AGF P.E., Bernard Chauvin Group, and previous shareholders RFINC [5 years]
Novagali ǂ 2006 .01 Clinical trial (phase II) for Cyclosporin derivative (completed) CLIN [5 years]
Novagali ǂ 2004 .12 2nd round-financing : 14.2 M€, with Edmond de Rothschild I.P., Siparex, and previous shareholders RFINB [4 years]
Novagali ǂ 2004 .09 Nomination : Jérôme Martinez as CEO ORGN [4 years]
Novagali ǂ 2000 .09 1st round-financing : 3.8 M€, with CDC Enterprise Innovation, Auriga Ventures, 123 Multinova, FJCE (CDC), Crédit Agricole P.E. RFINA [0 year]
Novagali ǂ 2000 .08 Company founded by Prof. Simon Benita (Israel) and others ORGF [0 year]
Novexel ǂ 2010 .03 Company move from Romainville to USA (premises down, 40 staffs out) ORGL [5 years]
Novexel ǂ 2009 .12 Acquisition by AstraZeneca (UK) for at least US$ 430 Millions ACQ- [5 years]
Novexel ǂ 2008 .11 Clinical trial (phase II) for combined NXL104/ceftazidime in Hospital Patients with complicated Urinary Tract Infections (beginning) CLIN [4 years]
Novexel ǂ 2008 .04 Licensing-out of NXL 104, a beta-lactamase inhibitor, to Forest (USA), with € 75 Millions upfront payment LICOUT [3 years]
Novexel ǂ 2008 .01 Set-up of US subsidiary in Pennsylvania ORGC [3 years]
Novexel ǂ 2007 .01 2nd round-financing : 50.0 M€, led by Edmond de Rothschild I.P., with Goldman Sachs, NeoMed, NIF SMBC, and previous shareholders RFINB [2 years]
Novexel ǂ 2006 .12 Licensing-in of Aminocandin from Indevus Biotech (USA) LICIN [2 years]
Novexel ǂ 2005 .10 Clinical trial (phase I) for NXL 103 (beginning) CLIN [1 year]
Novexel ǂ 2004 .12 1st round-financing : 40.0 M€, led by Atlas Venture, with Sofinnova, 3i, Abingworth, Novo RFINA [0 year]
Novexel ǂ 2004 .12 Company founded by Dominique Le Beller and others, as a spin-off from Sanofi-Aventis [ex-Aventis Pharma] ORGF [0 year]
Opi ǂ 2007 .03 Acquisition by Eusa Pharma (USA) ACQ- [8 years]
Opi ǂ 2004 .04 3rd round-financing : 6.4 M€, led by SPEF and Siparex, with previous shareholders RFINC [5 years]
Opi ǂ 2003 .05 Acquisition of Diaclone (France) ACQ+ [4 years]
Opi ǂ 2003 .00 2nd round-financing : 4.5 M€, by Sofimac, CDC-PME, Innoveris RFINB [3 years]
Opi ǂ 2001 .00 1st round-financing : 1.1 M€, by previous shareholders RFINA [1 year]
Opi ǂ 1999 .01 Company founded by Gilles Alberici [ex-Imtix, CEO], as 'Orphan Pharma International' ORGF [0 year]
Pharmaxon ǂ 2012 .01 Company simplified liquidation INFO [7 years]
Pharmaxon ǂ 2009 .11 1st round-financing : € 1.7 Million by SHAM (Société Hospitalière d'Assurances Mutuelles) and Primavéris RFINA [5 years]
Pharmaxon ǂ 2008 .11 Nomination : Glenn Stanley, as CEO, replacing Pascal Deschaseaux, moving as Gelarc Managing Director in Lyon (France) ORGN [4 years]
Pharmaxon ǂ 2007 .05 Licensing-in of PSA mimetic peptides from CNRS, 2 Universities and Schaffer-N (Denmark) LICIN [2 years]
Pharmaxon ǂ 2006 .10 Seed financing : 0.5 M€, by Inserm-Transfert Initiative, Esperante, Primavéris, Crédit Agricole AP Création SFIN [2 years]
Pharmaxon ǂ 2004 .09 Company founded by Pascal Deschaseaux [born 1960, M.D., MBA, ex-Pierre Fabre, Johnson & Johnson, Merck KGaA], Geneviève Rougon, Jean-Chrétien Norreel, as a spin-off from IBDM (Institut de Biologie et du Développement de Marseille-Luminy) ORGF [0 year]
PraXcell ǂ 2010 .10 Company liquidation INFO [6 years]
PraXcell ǂ 2007 .11 Round-financing : 1.5 M€, in preparation RFIN [4 years]
PraXcell ǂ 2006 .10 Seed financing : 0.5 M€, by Galia Gestion and Fonds d'Amorçage Midi Pyrénées SFIN [2 years]
PraXcell ǂ 2003 .11 Company founded by Dr Patrice Richard, Dr Lin Zeng, Michel Eymeri ORGF [0 year]
Protéus ǂ 2010 .09 Acquisition by PCAS (100%), after minority share in 2007 ACQ- [12 years]
Protéus ǂ 2007 .10 Round-financing : undisclosed M€, as a share capital increase reserved for industrial partner PCAS, from 6% to 32% RFIN [9 years]
Protéus ǂ 2005 .07 Set-up of PSI, new division to trade protein services and production ORGC [7 years]
Protéus ǂ 1999 .09 Seed financing : 0.2 M€, by Axa P.I., Natexis Ventech SFIN [1 year]
Protéus ǂ 1998 .01 Company founded by Daniel Dupret (CEO, then President up to 2007) [co-founder, born 1956, Eng. Insa, ex-Transgene, Appligene], Jean-François Bloch, Jean-Marie Sonet [PCAS] and others ORGF [0 year]
Sepal Pharma ǂ 2012 .06 Company simplified liquidation INFO [7 years]
Sepal Pharma ǂ 2008 .04 Nomination : Dr Frédéric Revah, as CEO ORGN [3 years]
Sepal Pharma ǂ 2007 .09 Management crisis : founder and CEO, Damien Salauze, on leave (for Institut Curie) ORG [3 years]
Sepal Pharma ǂ 2005 .06 Listing on LSE (London) : 3.8 M€ PBO [0 year]
Sepal Pharma ǂ 2004 .08 Company founded by Damien Salauze ([Pharm.D., MBA, ex-Auriga Partners, Rhône-Poulenc Rorer, Institut Pasteur], Christian Policard [ex-Sanofi], Max Herzberg and others, in Paris, with a subsidiary in Israel and a holding in London ORGF [0 year]
Serial Genetics ǂ 2010 .03 Company struck off LEGAL [6 years]
Serial Genetics ǂ 2009 .07 Partnering development agreement with Gendiag (Spain) for Thrombo InCode R&D [5 years]
Serial Genetics ǂ 2009 .06 Financing (no interest loan) : 9.0 M€, by OSEO Innovation, for the NOSOBIO program for prevention, diagnostics and treatment of hospital-acquired infections (with Oncodesign, Palumed, Da Volterra, Institut Pasteur and Assistance Publique-Hôpitaux de Paris) DEBT [5 years]
Serial Genetics ǂ 2006 .08 Seed financing : 0.4 M€, by undisclosed investors SFIN [2 years]
Serial Genetics ǂ 2003 .10 Company founded by Christophe Valat and François Nicolas ORGF [0 year]
ShigaMediX ǂ 2009 .06 Company liquidation INFO [3 years]
ShigaMediX ǂ 2007 .11 Partnering research agreement with GSK Biologicals on vaccines R&D [2 years]
ShigaMediX ǂ 2006 .10 Nomination : Jean-Marie Zacharie, as President and CEO ORGN [1 year]
ShigaMediX ǂ 2005 .08 Company founded by Ludger Johannes [Ph.D.] from Curie Institute/CNRS and Eric Tartour [M.D./Ph.D.] ORGF [0 year]
Synt:em ǂ 2006 .01 Acquisition by CLL Pharma (France), a development stage drug delivery pharmaceutical company, in shares ACQ- [11 years]
Synt:em ǂ 2004 .11 Acquisition (failed) by Sonus (USA), for 30 MUS$ in shares ACQ- [9 years]
Synt:em ǂ 1995 .00 Company founded by Michel Kaczorek (CEO), Caroline Roussel ORGF [0 year]
Theraptosis ǂ 2008 .12 Company liquidation (board of directors based decision) INFO [7 years]
Theraptosis ǂ 2007 .09 Nomination : Olivier Chesnoy [M.D.] as CEO ORGN [6 years]
Theraptosis ǂ 2007 .02 Company move to the Biocitech Park at Romainville (Paris North) ORGL [5 years]
Theraptosis ǂ 2006 .12 2nd round-financing : 8.4 M€, led by Auriga Partners, with Blue Medical, Seventure, Edmond de Rothschild (EdRIP), CDC entreprises (FCJE) RFINB [5 years]
Theraptosis ǂ 2006 .10 Registration : orphan drug designation by EMEA for a treatment of neonatal brain damage MKTG [5 years]
Theraptosis ǂ 2002 .07 1st round-financing : 2.5 M€, by undisclosed investors RFINA [1 year]
Theraptosis ǂ 2001 .03 Company founded by Léna Edelman and Etienne Jacotot, as a spin-off from Institut Pasteur, Paris ORGF [0 year]
Transat ǂ 2008 .03 Company liquidation INFO [5 years]
Transat ǂ 2006 .01 Seed financing : 1.2 M€, by Evolem, Oseo, Région Rhône-Alpes, and Philippe Desmarescaux (born 1938), as business angel SFIN [3 years]
Transat ǂ 2002 .12 Company founded by Sophie Chappuis and Marc Billaud (CNRS) ORGF [0 year]
UroGene ǂ 2011 .09 Company struck off LEGAL [13 years]
UroGene ǂ 2008 .08 No website news update since November 2006 (net capital : - 3 M€ in December 2006, but legal capital increases in September 2007, August 2008, August 2009, February 2010) INFO [10 years]
UroGene ǂ 2006 .01 Seed financing : 1.5 M€, by historical investors SFIN [7 years]
UroGene ǂ 2005 .01 Divestiture of drug discovery platform (including Chrysalon) to Pierre Fabre ACQ- [6 years]
UroGene ǂ 2004 .01 Licensing-in of Besipirdine exclusive rights from Aventis LICIN [5 years]
UroGene ǂ 2003 .03 2nd round-financing : 12.0 M€, led by Société Générale Asset Management (SGAM) RFINB [5 years]
UroGene ǂ 2002 .07 Acquisition of Chrysalon, a chemical company, spin-off from Aventis ACQ+ [4 years]
UroGene ǂ 2000 .12 Nomination : Christian Grenier [born 1950, Sup de Co Paris, MBA, ex-Rhône Poulenc], as CEO ORGN [2 years]
UroGene ǂ 2000 .09 1st round-financing : 2.0 M€, by Société Générale A.M., business angels RFINA [2 years]
UroGene ǂ 1998 .04 Seed financing : 1.5 M€, by founders and public funding SFIN [0 year]
UroGene ǂ 1998 .03 Company founded by Dr Philippe Berthon [CEO, Ph.D. cancerology], Dr Olivier Cussenot [CSO, Ph.D., M.D. surgery, Prof. urology], with Pierre Teillac [born 1960] and others ORGF [0 year]
Urrma ǂ 2010 .06 Company liquidation, with legal suite from Jean-Claude Chermann to minority shareholders INFO [9 years]
Urrma ǂ 2008 .03 3rd round-financing : 9.0 M€, by undisclosed investors RFINC [6 years]
Urrma ǂ 2005 .11 Round-financing : undisclosed M€, by private investors RFIN [4 years]
Urrma ǂ 2001 .06 Company founded by Prof. Jean-Claude Chermann, Camille Haslin and Urrma Biopharma, based in Montreal, as a J.V. with a French subsidiary, which has since August 2004 become a French independent legal entity ORGF [0 year]
Valigen ǂ 2002 .05 Company liquidation INFO [5 years]
Valigen ǂ 2001 .05 Nomination : Cécile Tharaud, as CEO ORGN [4 years]
Valigen ǂ 2000 .02 Acquisition of Kimeragen (USA), by merger ACQ+ [3 years]
Valigen ǂ 1997 .02 Acquisition of Infogen (Germany) ACQ+ [0 year]
Valigen ǂ 1996 .12 Company founded by Jean-Louis Pourny, from the merger of Valigène (France) and Kimeragen (USA) ORGF [0 year]
VigiCell ǂ 2010 .09 Company liquidation INFO [11 years]
VigiCell ǂ 2008 .11 Seed financing : 0.5 M€, by business angels and private investors (undisclosed) SFIN [9 years]
VigiCell ǂ 2007 .06 Partnering research agreement with L'Oréal R&D [8 years]
VigiCell ǂ 2002 .05 Nomination : Jean-Emmanuel Gilbert [Ph.D.], as CEO ORGN [2 years]
VigiCell ǂ 1999 .06 Company founded by Yolène Thomas [Ph.D., CNRS], Jean-Paul Oudinet [Ph.D., CNRS], Isaac Béhar [Ph.D.] and others ORGF [0 year]
Zeta Biotech ǂ 2010 .04 Company liquidation INFO [4 years]
Zeta Biotech ǂ 2008 .07 Production : set-up of full manufacturing line INDUS [2 years]
Zeta Biotech ǂ 2007 .06 Listing on Euronext Paris : 1.5 M€ PBO [1 year]
Zeta Biotech ǂ 2005 .10 Company founded by Antony Guyader and Bruno Viola ORGF [0 year]

Actualisation / Updating: Jan 15 2017


Pharmaclient est le site-conseil de la Valorisation Client en Pharma...
Pour toute Mission, Inscription à la Pharmagalerie, Insertion dans la base Biotech, ou Question: CONTACT



© J.H. Huber, Pharmaclient 2001-2017. Pour retourner à la page d'accueil Biotech: BIENVENUE !       Haut de page : légende